{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T22:32:58Z","timestamp":1774823578290,"version":"3.50.1"},"reference-count":238,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsche Forschungsgemeinschaft (DFG)"},{"name":"German Center for Cardiovascular Research (DZHK)"},{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>This review explores the interplay among metabolic dysfunction, oxidative stress, inflammation, and fibrosis in Fabry disease, focusing on their potential implications for cardiac involvement. We aim to discuss the biochemical processes that operate in parallel to sphingolipid accumulation and contribute to disease pathogenesis, emphasizing the importance of a comprehensive understanding of these processes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Beyond sphingolipid accumulation, emerging studies have revealed that mitochondrial dysfunction, oxidative stress, and chronic inflammation could be significant contributors to Fabry disease and cardiac involvement. These factors promote cardiac remodeling and fibrosis and may predispose Fabry patients to conduction disturbances, ventricular arrhythmias, and heart failure. While current treatments, such as enzyme replacement therapy and pharmacological chaperones, address disease progression and symptoms, their effectiveness is limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Our review uncovers the potential relationships among metabolic disturbances, oxidative stress, inflammation, and fibrosis in Fabry disease\u2013related cardiac complications. Current findings suggest that beyond sphingolipid accumulation, other mechanisms may significantly contribute to disease pathogenesis. This prompts the exploration of innovative therapeutic strategies and underscores the importance of a holistic approach to understanding and managing Fabry disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11897-024-00645-1","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T07:02:28Z","timestamp":1706598148000},"page":"81-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Fabry Disease: Cardiac Implications and Molecular Mechanisms"],"prefix":"10.1007","volume":"21","author":[{"given":"David","family":"Weissman","sequence":"first","affiliation":[]},{"given":"Jan","family":"Dudek","sequence":"additional","affiliation":[]},{"given":"Vasco","family":"Sequeira","sequence":"additional","affiliation":[]},{"given":"Christoph","family":"Maack","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"645_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. https:\/\/doi.org\/10.1186\/1750-1172-5-30.","journal-title":"Orphanet J Rare Dis"},{"key":"645_CR2","doi-asserted-by":"publisher","first-page":"813637","DOI":"10.3389\/fmolb.2022.813637","volume":"9","author":"AB Celi","year":"2022","unstructured":"Celi AB, Goldstein J, Rosato-Siri MV, Pinto A. Role of globotriaosylceramide in physiology and pathology. Front Mol Biosci. 2022;9:813637. https:\/\/doi.org\/10.3389\/fmolb.2022.813637.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"645_CR3","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1128\/iai.63.3.1138-1141.1995","volume":"63","author":"GT Keusch","year":"1995","unstructured":"Keusch GT, Jacewicz M, Acheson DW, Donohue-Rolfe A, Kane AV, McCluer RH. Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e. Infect Immun. 1995;63(3):1138\u201341. https:\/\/doi.org\/10.1128\/iai.63.3.1138-1141.1995.","journal-title":"Infect Immun"},{"issue":"2","key":"645_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.beem.2014.10.003","volume":"29","author":"N Seydelmann","year":"2015","unstructured":"Seydelmann N, Wanner C, St\u00f6rk S, Ertl G, Weidemann F. Fabry disease and the heart. Best Pract Res Clin Endocrinol Metab. 2015;29(2):195\u2013204. https:\/\/doi.org\/10.1016\/j.beem.2014.10.003.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"645_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet. 2009;46(8):548\u201352. https:\/\/doi.org\/10.1136\/jmg.2008.065904.","journal-title":"J Med Genet"},{"issue":"37","key":"645_CR6","doi-asserted-by":"publisher","first-page":"61415","DOI":"10.18632\/oncotarget.18250","volume":"8","author":"A Tuttolomondo","year":"2017","unstructured":"Tuttolomondo A, Simonetta I, Duro G, Pecoraro R, Miceli S, Colomba P, et al. Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson-Fabry disease. Oncotarget. 2017;8(37):61415\u201324. https:\/\/doi.org\/10.18632\/oncotarget.18250.","journal-title":"Oncotarget."},{"issue":"8","key":"645_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","volume":"57","author":"DP Germain","year":"2020","unstructured":"Germain DP, Oliveira JP, Bichet DG, Yoo HW, Hopkin RJ, Lemay R, et al. Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup. J Med Genet. 2020;57(8):542\u201351. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106467.","journal-title":"J Med Genet"},{"issue":"2","key":"645_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","volume":"41","author":"AB Burlina","year":"2018","unstructured":"Burlina AB, Polo G, Salviati L, Duro G, Zizzo C, Dardis A, et al. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis. 2018;41(2):209\u201319. https:\/\/doi.org\/10.1007\/s10545-017-0098-3.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"645_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jmg-2022-108523","volume":"60","author":"M Gilchrist","year":"2023","unstructured":"Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N, et al. Prevalence of Fabry disease-causing variants in the UK Biobank. J Med Genet. 2023;60(4):391\u20136. https:\/\/doi.org\/10.1136\/jmg-2022-108523.","journal-title":"J Med Genet"},{"issue":"9","key":"645_CR10","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/asn.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Brand E. Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. J Am Soc Nephrol. 2018;29(9):2265\u201378. https:\/\/doi.org\/10.1681\/asn.2018030329.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"645_CR11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","volume":"8","author":"M Lenders","year":"2022","unstructured":"Lenders M, Nordbeck P, Kurschat C, Eveslage M, Karabul N, Kaufeld J, et al. Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). Europ Heart J Cardiovasc Pharmacotherapy. 2022;8(3):272\u201381. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab025.","journal-title":"Europ Heart J Cardiovasc Pharmacotherapy"},{"issue":"1","key":"645_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.7150\/ijms.66448","volume":"19","author":"CL Lee","year":"2022","unstructured":"Lee CL, Lin SP, Niu DM, Lin HY. Fabry disease and the effectiveness of enzyme replacement therapy (ERT) in left ventricular hypertrophy (LVH) improvement: a review and meta-analysis. Int J Med Sci. 2022;19(1):126\u201331. https:\/\/doi.org\/10.7150\/ijms.66448.","journal-title":"Int J Med Sci"},{"issue":"1\u20132","key":"645_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ymgme.2022.08.003","volume":"137","author":"A Nowak","year":"2022","unstructured":"Nowak A, Dormond O, Monzambani V, Huynh-Do U, Barbey F. Agalsidase-\u03b2 should be proposed as first line therapy in classic male Fabry patients with undetectable \u03b1-galactosidase A activity. Mol Gen Metab. 2022;137(1\u20132):173\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2022.08.003.\u00a0","journal-title":"Mol Gen Metab."},{"key":"645_CR14","doi-asserted-by":"publisher","unstructured":"Umer M, Kalra DK. Treatment of Fabry disease: established and emerging therapies. Pharmaceuticals. 2023;16(2):320. https:\/\/doi.org\/10.3390\/ph16020320.","DOI":"10.3390\/ph16020320"},{"key":"645_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.omtm.2020.08.012","volume":"19","author":"M Lenders","year":"2020","unstructured":"Lenders M, Stappers F, Brand E. In vitro and in vivo amenability to migalastat in Fabry disease. Mol Ther Methods Clin Dev. 2020;19:24\u201334. https:\/\/doi.org\/10.1016\/j.omtm.2020.08.012.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"645_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2119\/molmed.2015.00088","volume":"21","author":"KM Ashe","year":"2015","unstructured":"Ashe KM, Budman E, Bangari DS, Siegel CS, Nietupski JB, Wang B, et al. Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. Mol Med. 2015;21:389\u201399. https:\/\/doi.org\/10.2119\/molmed.2015.00088.","journal-title":"Mol Med"},{"key":"645_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1750-1172-4-21","volume":"4","author":"B Hoffmann","year":"2009","unstructured":"Hoffmann B. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009;4:21. https:\/\/doi.org\/10.1186\/1750-1172-4-21.","journal-title":"Orphanet J Rare Dis"},{"key":"645_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47. https:\/\/doi.org\/10.1186\/1750-1172-8-47.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"645_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.echo.2013.09.005","volume":"26","author":"M Shanks","year":"2013","unstructured":"Shanks M, Thompson RB, Paterson ID, Putko B, Khan A, Chan A, et al. Systolic and diastolic function assessment in Fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements. J Amer Soc Echocardiogr. 2013;26(12):1407\u201314. https:\/\/doi.org\/10.1016\/j.echo.2013.09.005.","journal-title":"J Amer Soc Echocardiogr"},{"issue":"6","key":"645_CR20","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","volume":"114","author":"J Kr\u00e4mer","year":"2014","unstructured":"\u2022 Kr\u00e4mer J, Niemann M, St\u00f6rk S, Frantz S, Beer M, Ertl G, et al. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol. 2014;114(6):895\u2013900. https:\/\/doi.org\/10.1016\/j.amjcard.2014.06.019. (In Fabry disease, myocardial fibrosis strongly predicts malignant ventricular arrhythmias.)","journal-title":"Am J Cardiol"},{"issue":"11","key":"645_CR21","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/eurheartj\/ehs166","volume":"34","author":"Z Yousef","year":"2013","unstructured":"Yousef Z, Elliott PM, Cecchi F, Escoubet B, Linhart A, Monserrat L, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J. 2013;34(11):802\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehs166.","journal-title":"Eur Heart J"},{"issue":"6","key":"645_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.echo.2018.01.016","volume":"31","author":"DF Yeung","year":"2018","unstructured":"Yeung DF, Sirrs S, Tsang MYC, Gin K, Luong C, Jue J, et al. Echocardiographic assessment of patients with Fabry disease. J Amer Soc Echocardiogr. 2018;31(6):639-49.e2. https:\/\/doi.org\/10.1016\/j.echo.2018.01.016.","journal-title":"J Amer Soc Echocardiogr"},{"key":"645_CR23","doi-asserted-by":"publisher","unstructured":"Tuttolomondo A, Simonetta I, Riolo R, Todaro F, Di Chiara T, Miceli S, et al. Pathogenesis and molecular mechanisms of Anderson-Fabry disease and possible new molecular addressed therapeutic strategies. Int J Mol Sci. 2021;22(18):10088. https:\/\/doi.org\/10.3390\/ijms221810088.","DOI":"10.3390\/ijms221810088"},{"issue":"19","key":"645_CR24","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1161\/circulationaha.108.841494","volume":"119","author":"BL Thurberg","year":"2009","unstructured":"Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O\u2019Callaghan MW. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation. 2009;119(19):2561\u20137. https:\/\/doi.org\/10.1161\/circulationaha.108.841494.","journal-title":"Circulation"},{"issue":"6","key":"645_CR25","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.humpath.2006.01.021","volume":"37","author":"CL Owens","year":"2006","unstructured":"Owens CL, Russell SD, Halushka MK. Histologic and electron microscopy findings in myocardium of treated Fabry disease. Hum Pathol. 2006;37(6):764\u20138. https:\/\/doi.org\/10.1016\/j.humpath.2006.01.021.","journal-title":"Hum Pathol"},{"issue":"2","key":"645_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","volume":"99","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010;99(2):99\u2013108. https:\/\/doi.org\/10.1016\/j.ymgme.2009.10.004.","journal-title":"Mol Genet Metab"},{"issue":"17","key":"645_CR27","doi-asserted-by":"publisher","first-page":"e009052","DOI":"10.1161\/jaha.118.009052","volume":"7","author":"A Frustaci","year":"2018","unstructured":"\u2022 Frustaci A, Verardo R, Grande C, Galea N, Piselli P, Carbone I, et al. Immune-mediated myocarditis in Fabry disease cardiomyopathy. J Am Heart Assoc. 2018;7(17):e009052. https:\/\/doi.org\/10.1161\/jaha.118.009052. (Up to 56% of patients with Fabry cardiomyopathy exhibit histologically detectable myocarditis, potentially affecting treatment response.)","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"645_CR28","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.2353\/ajpath.2008.070576","volume":"172","author":"C Chimenti","year":"2008","unstructured":"\u2022 Chimenti C, Hamdani N, Boontje NM, DeCobelli F, Esposito A, Bronzwaer JG, et al. Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol. 2008;172(6):1482\u201390. https:\/\/doi.org\/10.2353\/ajpath.2008.070576. (Fabry cardiomyopathy is linked to myofilament degradation and dysfunction.)","journal-title":"Am J Pathol"},{"issue":"7","key":"645_CR29","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","volume":"77","author":"M Pieroni","year":"2021","unstructured":"Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC, et al. Cardiac involvement in Fabry disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(7):922\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.024.","journal-title":"J Am Coll Cardiol"},{"key":"645_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fcvm.2016.00007","volume":"3","author":"M Namdar","year":"2016","unstructured":"Namdar M. Electrocardiographic changes and arrhythmia in Fabry disease. Front Cardiovasc Med. 2016;3:7. https:\/\/doi.org\/10.3389\/fcvm.2016.00007.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"645_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.stemcr.2019.07.004","volume":"13","author":"MJ Birket","year":"2019","unstructured":"Birket MJ, Raibaud S, Lettieri M, Adamson AD, Letang V, Cervello P, et al. A human stem cell model of Fabry disease implicates LIMP-2 accumulation in cardiomyocyte pathology. Stem Cell Rep. 2019;13(2):380\u201393. https:\/\/doi.org\/10.1016\/j.stemcr.2019.07.004.","journal-title":"Stem Cell Rep"},{"issue":"3","key":"645_CR32","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/ehf2.12723","volume":"7","author":"A Frustaci","year":"2020","unstructured":"Frustaci A, Scarpa M, Maria da Riol R, Agrati C, Finato N, Verardo R, et al. Fabry cardiomyopathy: Gb3-induced auto-reactive panmyocarditis requiring heart transplantation. ESC Heart Fail. 2020;7(3):1331\u20137. https:\/\/doi.org\/10.1002\/ehf2.12723.","journal-title":"ESC Heart Fail."},{"key":"645_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/8904_2014_371","volume":"22","author":"W Mauhin","year":"2015","unstructured":"Mauhin W, Lidove O, Masat E, Mingozzi F, Mariampillai K, Ziza JM, et al. Innate and adaptive immune response in Fabry disease. JIMD Rep. 2015;22:1\u201310. https:\/\/doi.org\/10.1007\/8904_2014_371.","journal-title":"JIMD Rep"},{"issue":"3","key":"645_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017;122(3):19\u201327. https:\/\/doi.org\/10.1016\/j.ymgme.2017.09.004.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"645_CR35","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11886-023-01877-8","volume":"25","author":"A Hara","year":"2023","unstructured":"Hara A, Tallquist MD. Fibroblast and immune cell cross-talk in cardiac fibrosis. Curr Cardiol Rep. 2023;25(6):485\u201393. https:\/\/doi.org\/10.1007\/s11886-023-01877-8.","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"645_CR36","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28(10):1228\u201335. https:\/\/doi.org\/10.1093\/eurheartj\/ehm153.","journal-title":"Eur Heart J"},{"issue":"7","key":"645_CR37","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ejhf.1960","volume":"22","author":"A Linhart","year":"2020","unstructured":"Linhart A, Germain DP, Olivotto I, Akhtar MM, Anastasakis A, Hughes D, et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail. 2020;22(7):1076\u201396. https:\/\/doi.org\/10.1002\/ejhf.1960.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"645_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/circheartfailure.108.769729","volume":"1","author":"C Chimenti","year":"2008","unstructured":"Chimenti C, Morgante E, Tanzilli G, Mangieri E, Critelli G, Gaudio C, et al. Angina in Fabry disease reflects coronary small vessel disease. Circ Heart Fail. 2008;1(3):161\u20139. https:\/\/doi.org\/10.1161\/circheartfailure.108.769729.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"645_CR39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.echo.2021.09.013","volume":"35","author":"H Yogasundaram","year":"2022","unstructured":"Yogasundaram H, Nikhanj A, Chatur S, Qi A, Hagen L, Bailey L, et al. Burden of valvular heart disease in patients with Fabry disease. J Amer Soc Echocardiogr. 2022;35(2):236\u20138. https:\/\/doi.org\/10.1016\/j.echo.2021.09.013.","journal-title":"J Amer Soc Echocardiogr"},{"key":"645_CR40","doi-asserted-by":"publisher","unstructured":"\u2022 Machann W, Breunig F, Weidemann F, Sandstede J, Hahn D, K\u00f6stler H, et al. Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A. Europ J Heart Fail. 2011;13(3):278-83. https:\/\/doi.org\/10.1093\/eurjhf\/hfq211. (Lower levels of energy-carrying molecules in the heart of Fabry patients are partially restored by enzyme replacement therapy.)","DOI":"10.1093\/eurjhf\/hfq211"},{"issue":"8","key":"645_CR41","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.3390\/jcm9082596","volume":"9","author":"KM Stepien","year":"2020","unstructured":"Stepien KM, Roncaroli F, Turton N, Hendriksz CJ, Roberts M, Heaton RA, et al. Mechanisms of mitochondrial dysfunction in lysosomal storage disorders: a review. J Clin Med. 2020;9(8):2596. https:\/\/doi.org\/10.3390\/jcm9082596.","journal-title":"J Clin Med."},{"issue":"2","key":"645_CR42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.molmed.2016.12.003","volume":"23","author":"N Plotegher","year":"2017","unstructured":"Plotegher N, Duchen MR. Mitochondrial dysfunction and neurodegeneration in lysosomal storage disorders. Trends Mol Med. 2017;23(2):116\u201334. https:\/\/doi.org\/10.1016\/j.molmed.2016.12.003.","journal-title":"Trends Mol Med"},{"issue":"2","key":"645_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijcard.2009.03.045","volume":"144","author":"T Palecek","year":"2010","unstructured":"\u2022 Palecek T, Bultas J, Hajek M, Karetova D, Kuchynka P, Kautzner J, et al. Association between cardiac energy metabolism and gain of left ventricular mass in Fabry disease. Int J Cardiol. 2010;144(2):337\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2009.03.045. (Cardiac energy metabolism negatively correlates with the annual increase in LV mass in Fabry disease, suggesting an association with the progression of Fabry cardiomyopathy.)","journal-title":"Int J Cardiol"},{"issue":"3","key":"645_CR44","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3390\/ijms24032044","volume":"24","author":"Z Granek","year":"2023","unstructured":"Granek Z, Barczuk J, Siwecka N, Rozp\u0119dek-Kami\u0144ska W, Kucharska E, Majsterek I. GBA1 gene mutations in \u03b1-synucleinopathies-molecular mechanisms underlying pathology and their clinical significance. Int J Mol Sci. 2023;24(3):2044. https:\/\/doi.org\/10.3390\/ijms24032044.","journal-title":"Int J Mol Sci."},{"issue":"5","key":"645_CR45","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41418-019-0442-2","volume":"27","author":"N Plotegher","year":"2020","unstructured":"Plotegher N, Perocheau D, Ferrazza R, Massaro G, Bhosale G, Zambon F, et al. Impaired cellular bioenergetics caused by GBA1 depletion sensitizes neurons to calcium overload. Cell Death Differ. 2020;27(5):1588\u2013603. https:\/\/doi.org\/10.1038\/s41418-019-0442-2.","journal-title":"Cell Death Differ"},{"issue":"15","key":"645_CR46","doi-asserted-by":"publisher","first-page":"15856","DOI":"10.18632\/aging.103794","volume":"12","author":"S Taverna","year":"2020","unstructured":"Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, et al. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging. 2020;12(15):15856\u201374. https:\/\/doi.org\/10.18632\/aging.103794.","journal-title":"Aging."},{"issue":"1","key":"645_CR47","doi-asserted-by":"publisher","first-page":"13473","DOI":"10.1038\/s41598-017-14063-y","volume":"7","author":"T Yoshida","year":"2017","unstructured":"Yoshida T, Awaya T, Jonouchi T, Kimura R, Kimura S, Era T, et al. A skeletal muscle model of infantile-onset pompe disease with patient-specific iPS cells. Sci Rep. 2017;7(1):13473. https:\/\/doi.org\/10.1038\/s41598-017-14063-y.","journal-title":"Sci Rep"},{"issue":"1","key":"645_CR48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ymgme.2004.01.011","volume":"82","author":"T L\u00fccke","year":"2004","unstructured":"L\u00fccke T, H\u00f6ppner W, Schmidt E, Illsinger S, Das AM. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab. 2004;82(1):93\u20137. https:\/\/doi.org\/10.1016\/j.ymgme.2004.01.011.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"645_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210617","volume":"14","author":"MM Ivanova","year":"2019","unstructured":"Ivanova MM, Changsila E, Iaonou C, Goker-Alpan O. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases. PLoS ONE. 2019;14(1): e0210617. https:\/\/doi.org\/10.1371\/journal.pone.0210617.","journal-title":"PLoS ONE"},{"issue":"4","key":"645_CR50","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/jimd.12373","volume":"44","author":"A Schumann","year":"2021","unstructured":"Schumann A, Schaller K, Belche V, Cybulla M, Gr\u00fcnert SC, Moers N, et al. Defective lysosomal storage in Fabry disease modifies mitochondrial structure, metabolism and turnover in renal epithelial cells. J Inherit Metab Dis. 2021;44(4):1039\u201350. https:\/\/doi.org\/10.1002\/jimd.12373.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"645_CR51","doi-asserted-by":"publisher","first-page":"575","DOI":"10.7150\/ijbs.7.575","volume":"7","author":"X Li","year":"2011","unstructured":"Li X, Kazgan N. Mammalian sirtuins and energy metabolism. Int J Biol Sci. 2011;7(5):575\u201387. https:\/\/doi.org\/10.7150\/ijbs.7.575.","journal-title":"Int J Biol Sci"},{"key":"645_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijcard.2017.01.009","volume":"232","author":"SJ Chou","year":"2017","unstructured":"\u2022 Chou SJ, Yu WC, Chang YL, Chen WY, Chang WC, Chien Y, et al. Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease. Int J Cardiol. 2017;232:255\u201363. https:\/\/doi.org\/10.1016\/j.ijcard.2017.01.009. (iPSCs from Fabry patients show reduced \u03b1-Gal A activity and a metabolic shift to glycolysis for energy metabolism. ERT did not amend this shift.)","journal-title":"Int J Cardiol"},{"issue":"4","key":"645_CR53","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","volume":"131","author":"D Reczek","year":"2007","unstructured":"Reczek D, Schwake M, Schr\u00f6der J, Hughes H, Blanz J, Jin X, et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell. 2007;131(4):770\u201383. https:\/\/doi.org\/10.1016\/j.cell.2007.10.018.","journal-title":"Cell"},{"key":"645_CR54","doi-asserted-by":"publisher","unstructured":"Zou Y, Pei J, Wang Y, Chen Q, Sun M, Kang L, et al. The deficiency of SCARB2\/LIMP-2 impairs metabolism via disrupted mTORC1-dependent mitochondrial OXPHOS. Int J Mol Sci. 2022;23(15):8634. https:\/\/doi.org\/10.3390\/ijms23158634.","DOI":"10.3390\/ijms23158634"},{"issue":"2","key":"645_CR55","doi-asserted-by":"publisher","first-page":"C155","DOI":"10.1152\/ajpcell.00227.2014","volume":"308","author":"W Tigchelaar","year":"2015","unstructured":"Tigchelaar W, Yu H, de Jong AM, van Gilst WH, van der Harst P, Westenbrink BD, et al. Loss of mitochondrial exo\/endonuclease EXOG affects mitochondrial respiration and induces ROS-mediated cardiomyocyte hypertrophy. Am J Physiol Cell Physiol. 2015;308(2):C155\u201363. https:\/\/doi.org\/10.1152\/ajpcell.00227.2014.","journal-title":"Am J Physiol Cell Physiol"},{"key":"645_CR56","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.freeradbiomed.2021.05.013","volume":"171","author":"D Weissman","year":"2021","unstructured":"Weissman D, Maack C. Redox signaling in heart failure and therapeutic implications. Free Radical Biol Med. 2021;171:345\u201364. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.05.013.","journal-title":"Free Radical Biol Med"},{"issue":"2","key":"645_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bbrc.2017.03.030","volume":"486","author":"KH Chen","year":"2017","unstructured":"Chen KH, Chou YC, Hsiao CY, Chien Y, Wang KL, Lai YH, et al. Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy. Biochem Biophys Res Commun. 2017;486(2):293\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2017.03.030.","journal-title":"Biochem Biophys Res Commun"},{"key":"645_CR58","doi-asserted-by":"crossref","unstructured":"Korkmaz KS, Butuner BD, Roggenbuck DJJOL, Medicine P. Detection of 8-OHdG as a diagnostic biomarker. J Lab Precis Med. 2018;3:95","DOI":"10.21037\/jlpm.2018.11.01"},{"issue":"12","key":"645_CR59","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1007\/s00415-020-10044-w","volume":"267","author":"C Simoncini","year":"2020","unstructured":"Simoncini C, Torri S, Montano V, Chico L, Gruosso F, Tuttolomondo A, et al. Oxidative stress biomarkers in Fabry disease: is there a room for them? J Neurol. 2020;267(12):3741\u201352. https:\/\/doi.org\/10.1007\/s00415-020-10044-w.","journal-title":"J Neurol"},{"issue":"11","key":"645_CR60","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.humpath.2015.07.017","volume":"46","author":"C Chimenti","year":"2015","unstructured":"\u2022 Chimenti C, Scopelliti F, Vulpis E, Tafani M, Villanova L, Verardo R, et al. Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy. Hum Pathol. 2015;46(11):1760\u20138. https:\/\/doi.org\/10.1016\/j.humpath.2015.07.017. (Cardiac dysfunction in Fabry disease is linked to increased oxidative stress, with heightened nitric oxide production causing oxidative damage to cardiomyocyte and cell death.)","journal-title":"Hum Pathol"},{"issue":"6","key":"645_CR61","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/hmg\/ddx032","volume":"26","author":"JS Shen","year":"2017","unstructured":"Shen JS, Arning E, West ML, Day TS, Chen S, Meng XL, et al. Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease. Hum Mol Genet. 2017;26(6):1182\u201392. https:\/\/doi.org\/10.1093\/hmg\/ddx032.","journal-title":"Hum Mol Genet"},{"issue":"22","key":"645_CR62","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.2174\/13816128113196660746","volume":"20","author":"S Luo","year":"2014","unstructured":"Luo S, Lei H, Qin H, Xia Y. Molecular mechanisms of endothelial NO synthase uncoupling. Curr Pharm Des. 2014;20(22):3548\u201353. https:\/\/doi.org\/10.2174\/13816128113196660746.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"645_CR63","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1382-6689(01)00077-1","volume":"10","author":"NH Cnubben","year":"2001","unstructured":"Cnubben NH, Rietjens IM, Wortelboer H, van Zanden J, van Bladeren PJ. The interplay of glutathione-related processes in antioxidant defense. Environ Toxicol Pharmacol. 2001;10(4):141\u201352. https:\/\/doi.org\/10.1016\/s1382-6689(01)00077-1.","journal-title":"Environ Toxicol Pharmacol"},{"issue":"3","key":"645_CR64","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3727\/096368916x694265","volume":"26","author":"WL Tseng","year":"2017","unstructured":"Tseng WL, Chou SJ, Chiang HC, Wang ML, Chien CS, Chen KH, et al. Imbalanced production of reactive oxygen species and mitochondrial antioxidant SOD2 in Fabry disease-specific human induced pluripotent stem cell-differentiated vascular endothelial cells. Cell Transplant. 2017;26(3):513\u201327. https:\/\/doi.org\/10.3727\/096368916x694265.","journal-title":"Cell Transplant"},{"issue":"6","key":"645_CR65","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/joim.12268","volume":"276","author":"HD Grahame","year":"2014","unstructured":"Grahame HD. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J Intern Med. 2014;276(6):543\u201359. https:\/\/doi.org\/10.1111\/joim.12268.","journal-title":"J Intern Med"},{"issue":"10","key":"645_CR66","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s12276-021-00683-y","volume":"53","author":"JW Kim","year":"2021","unstructured":"Kim JW, Kim HW, Nam SA, Lee JY, Cho HJ, Kim TM, et al. Human kidney organoids reveal the role of glutathione in Fabry disease. Exp Mol Med. 2021;53(10):1580\u201391. https:\/\/doi.org\/10.1038\/s12276-021-00683-y.","journal-title":"Exp Mol Med"},{"issue":"2","key":"645_CR67","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG, et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochem Biophys Acta. 2012;1822(2):226\u201332. https:\/\/doi.org\/10.1016\/j.bbadis.2011.11.001.","journal-title":"Biochem Biophys Acta"},{"key":"645_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mrgentox.2015.04.012","volume":"784\u2013785","author":"GB Biancini","year":"2015","unstructured":"Biancini GB, Moura DJ, Manini PR, Faverzani JL, Netto CB, Deon M, et al. DNA damage in Fabry patients: an investigation of oxidative damage and repair. Mutat Res Genet Toxicol Environ Mutagen. 2015;784\u2013785:31\u20136. https:\/\/doi.org\/10.1016\/j.mrgentox.2015.04.012.","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"645_CR69","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cca.2016.07.016","volume":"461","author":"GB Biancini","year":"2016","unstructured":"Biancini GB, Jacques CE, Hammerschmidt T, de Souza HM, Donida B, Deon M, et al. Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy. Clin Chim Acta: Int J Clin Chem. 2016;461:41\u20136. https:\/\/doi.org\/10.1016\/j.cca.2016.07.016.","journal-title":"Clin Chim Acta: Int J Clin Chem."},{"issue":"1","key":"645_CR70","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5966\/sctm.2015-0409","volume":"6","author":"Y Sato","year":"2017","unstructured":"Sato Y, Kobayashi H, Higuchi T, Shimada Y, Ida H, Ohashi T. Metabolomic profiling of Pompe disease-induced pluripotent stem cell-derived cardiomyocytes reveals that oxidative stress is associated with cardiac and skeletal muscle pathology. Stem Cells Transl Med. 2017;6(1):31\u20139. https:\/\/doi.org\/10.5966\/sctm.2015-0409.","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"645_CR71","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1034\/j.1399-0004.2003.00147.x","volume":"64","author":"MT Vanier","year":"2003","unstructured":"Vanier MT, Millat G. Niemann-Pick disease type C. Clin Genet. 2003;64(4):269\u201381. https:\/\/doi.org\/10.1034\/j.1399-0004.2003.00147.x.","journal-title":"Clin Genet"},{"key":"645_CR72","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.pbiomolbio.2018.03.001","volume":"140","author":"H Sepasi Tehrani","year":"2018","unstructured":"Sepasi Tehrani H, Moosavi-Movahedi AA. Catalase and its mysteries. Prog Biophys Mol Biol. 2018;140:5\u201312. https:\/\/doi.org\/10.1016\/j.pbiomolbio.2018.03.001.","journal-title":"Prog Biophys Mol Biol"},{"issue":"20","key":"645_CR73","doi-asserted-by":"publisher","first-page":"7667","DOI":"10.3390\/ijms21207667","volume":"21","author":"AV J\u00fcrs","year":"2020","unstructured":"J\u00fcrs AV, V\u00f6lkner C, Liedtke M, Huth K, Lukas J, Hermann A, et al. Oxidative stress and alterations in the antioxidative defense system in neuronal cells derived from NPC1 patient-specific induced pluripotent stem cells. Int J Mol Sci. 2020;21(20):7667. https:\/\/doi.org\/10.3390\/ijms21207667.","journal-title":"Int J Mol Sci."},{"key":"645_CR74","doi-asserted-by":"publisher","first-page":"10903","DOI":"10.1038\/srep10903","volume":"5","author":"M de la Mata","year":"2015","unstructured":"de la Mata M, Cot\u00e1n D, Oropesa-\u00c1vila M, Garrido-Maraver J, Cordero MD, Villanueva Paz M, et al. Pharmacological chaperones and coenzyme Q10 treatment improves mutant \u03b2-glucocerebrosidase activity and mitochondrial function in neuronopathic forms of Gaucher disease. Sci Rep. 2015;5:10903. https:\/\/doi.org\/10.1038\/srep10903.","journal-title":"Sci Rep"},{"issue":"5","key":"645_CR75","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11(5):373\u201384. https:\/\/doi.org\/10.1038\/ni.1863.","journal-title":"Nat Immunol"},{"issue":"2","key":"645_CR76","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","volume":"20","author":"T Gong","year":"2020","unstructured":"Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20(2):95\u2013112. https:\/\/doi.org\/10.1038\/s41577-019-0215-7.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"645_CR77","doi-asserted-by":"publisher","DOI":"10.4110\/in.2018.18.e27","volume":"18","author":"JS Roh","year":"2018","unstructured":"Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Netw. 2018;18(4): e27. https:\/\/doi.org\/10.4110\/in.2018.18.e27.","journal-title":"Immune Netw"},{"issue":"6","key":"645_CR78","doi-asserted-by":"publisher","first-page":"7204","DOI":"10.18632\/oncotarget.23208","volume":"9","author":"L Chen","year":"2018","unstructured":"Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204\u201318. https:\/\/doi.org\/10.18632\/oncotarget.23208.","journal-title":"Oncotarget."},{"issue":"10","key":"645_CR79","doi-asserted-by":"publisher","first-page":"1221.e1","DOI":"10.1016\/j.cjca.2015.10.033","volume":"32","author":"KH Chen","year":"2016","unstructured":"Chen KH, Chien Y, Wang KL, Leu HB, Hsiao CY, Lai YH, et al. Evaluation of proinflammatory prognostic biomarkers for Fabry cardiomyopathy with enzyme replacement therapy. Can J Cardiol. 2016;32(10):1221.e1-e9. https:\/\/doi.org\/10.1016\/j.cjca.2015.10.033.","journal-title":"Can J Cardiol."},{"issue":"21","key":"645_CR80","doi-asserted-by":"publisher","first-page":"e009098","DOI":"10.1161\/jaha.118.009098","volume":"7","author":"H Yogasundaram","year":"2018","unstructured":"\u2022 Yogasundaram H, Nikhanj A, Putko BN, Boutin M, Jain-Ghai S, Khan A, et al. Elevated inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction. J Am Heart Assoc. 2018;7(21):e009098. https:\/\/doi.org\/10.1161\/jaha.118.009098. (Inflammatory and cardiac remodeling biomarkers correlate with disease progression. Enzyme replacement therapy shows limited effectiveness in severe cases.)","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"645_CR81","first-page":"205","volume":"10","author":"V Barak","year":"1999","unstructured":"Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, et al. Cytokines in Gaucher\u2019s disease. Eur Cytokine Netw. 1999;10(2):205\u201310.","journal-title":"Eur Cytokine Netw"},{"issue":"6","key":"645_CR82","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/j.1442-200X.2007.02502.x","volume":"49","author":"M Yoshino","year":"2007","unstructured":"Yoshino M, Watanabe Y, Tokunaga Y, Harada E, Fujii C, Numata S, et al. Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease. Pediatr Int. 2007;49(6):959\u201365. https:\/\/doi.org\/10.1111\/j.1442-200X.2007.02502.x.","journal-title":"Pediatr Int"},{"issue":"2","key":"645_CR83","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","volume":"23","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Evers L, Aerts JM, van Oers MH. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis. 1997;23(2):201\u201312. https:\/\/doi.org\/10.1006\/bcmd.1997.0137.","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"645_CR84","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","volume":"1772","author":"MJ van Breemen","year":"2007","unstructured":"van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, Maas M, et al. Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochem Biophys Acta. 2007;1772(7):788\u201396. https:\/\/doi.org\/10.1016\/j.bbadis.2007.04.002.","journal-title":"Biochem Biophys Acta"},{"issue":"1","key":"645_CR85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bcmd.2010.10.010","volume":"46","author":"EV Pavlova","year":"2011","unstructured":"Pavlova EV, Deegan PB, Tindall J, McFarlane I, Mehta A, Hughes D, et al. Potential biomarkers of osteonecrosis in Gaucher disease. Blood Cells Mol Dis. 2011;46(1):27\u201333. https:\/\/doi.org\/10.1016\/j.bcmd.2010.10.010.","journal-title":"Blood Cells Mol Dis"},{"issue":"457","key":"645_CR86","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1651-2227.2007.00641.x","volume":"97","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, van Breemen MJ, Bussink AP, Ghauharali K, Sprenger R, Boot RG, et al. Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatr. 2008;97(457):7\u201314. https:\/\/doi.org\/10.1111\/j.1651-2227.2007.00641.x.","journal-title":"Acta Paediatr."},{"key":"645_CR87","doi-asserted-by":"publisher","unstructured":"Szyma\u0144ska-Ro\u017cek P, Czartoryska B, Kleinotiene G, Lipi\u0144ski P, Tylki-Szyma\u0144ska A, \u0141ugowska A. A 20-year longitudinal study of plasma chitotriosidase activity in treated Gaucher disease type 1 and 3 patients-a qualitative and quantitative approach. Biomolecules. 2023;13(3):436. https:\/\/doi.org\/10.3390\/biom13030436.","DOI":"10.3390\/biom13030436"},{"issue":"3","key":"645_CR88","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ymgme.2006.04.013","volume":"89","author":"AC Vedder","year":"2006","unstructured":"Vedder AC, Cox-Brinkman J, Hollak CE, Linthorst GE, Groener JE, Helmond MT, et al. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. Mol Genet Metab. 2006;89(3):239\u201344. https:\/\/doi.org\/10.1016\/j.ymgme.2006.04.013.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"645_CR89","doi-asserted-by":"publisher","first-page":"113175","DOI":"10.1016\/j.yexcr.2022.113175","volume":"416","author":"TG Hammerschmidt","year":"2022","unstructured":"Hammerschmidt TG, Donida B, Faverzani JL, Moura AP, Dos Reis BG, Machado AZ, et al. Cytokine profile and cholesterol levels in patients with Niemann-Pick type C disease presenting neurological symptoms: in vivo effect of miglustat and in vitro effect of N-acetylcysteine and coenzyme Q10. Exp Cell Res. 2022;416(2):113175. https:\/\/doi.org\/10.1016\/j.yexcr.2022.113175.","journal-title":"Exp Cell Res"},{"issue":"6","key":"645_CR90","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s10753-015-0214-1","volume":"38","author":"Y Hayashi","year":"2015","unstructured":"Hayashi Y, Hanawa H, Jiao S, Hasegawa G, Ohno Y, Yoshida K, et al. Elevated endomyocardial biopsy macrophage-related markers in intractable myocardial diseases. Inflammation. 2015;38(6):2288\u201399. https:\/\/doi.org\/10.1007\/s10753-015-0214-1.","journal-title":"Inflammation"},{"issue":"Suppl 1","key":"645_CR91","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1007\/s10545-009-1060-9","volume":"32","author":"P Rozenfeld","year":"2009","unstructured":"Rozenfeld P, Agriello E, De Francesco N, Martinez P, Fossati C. Leukocyte perturbation associated with Fabry disease. J Inherit Metab Dis. 2009;32(Suppl 1):S67-77. https:\/\/doi.org\/10.1007\/s10545-009-1060-9.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"645_CR92","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1365-2141.2005.05503.x","volume":"129","author":"A Balreira","year":"2005","unstructured":"Balreira A, Lacerda L, Miranda CS, Arosa FA. Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model. Br J Haematol. 2005;129(5):667\u201376. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05503.x.","journal-title":"Br J Haematol"},{"issue":"12","key":"645_CR93","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nri2191","volume":"7","author":"DC Barral","year":"2007","unstructured":"Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol. 2007;7(12):929\u201341. https:\/\/doi.org\/10.1038\/nri2191.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"645_CR94","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/imr.12435","volume":"272","author":"S Afridi","year":"2016","unstructured":"Afridi S, Hoessli DC, Hameed MW. Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications. Immunol Rev. 2016;272(1):151\u201368. https:\/\/doi.org\/10.1111\/imr.12435.","journal-title":"Immunol Rev"},{"issue":"4","key":"645_CR95","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ymgme.2013.01.018","volume":"108","author":"CS Pereira","year":"2013","unstructured":"Pereira CS, Azevedo O, Maia ML, Dias AF, Sa-Miranda C, Macedo MF. Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease. Mol Genet Metab. 2013;108(4):241\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2013.01.018.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"645_CR96","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1182\/blood-2014-09-600270","volume":"125","author":"S Nair","year":"2015","unstructured":"Nair S, Boddupalli CS, Verma R, Liu J, Yang R, Pastores GM, et al. Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. Blood. 2015;125(8):1256\u201371. https:\/\/doi.org\/10.1182\/blood-2014-09-600270.","journal-title":"Blood"},{"issue":"1","key":"645_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/irdr.2020.01011","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res. 2020;9(1):1\u20139. https:\/\/doi.org\/10.5582\/irdr.2020.01011.","journal-title":"Intractable Rare Dis Res"},{"key":"645_CR98","doi-asserted-by":"publisher","unstructured":"Lopes N, Maia ML, Pereira CS, Mondrag\u00e3o-Rodrigues I, Martins E, Ribeiro R, et al. Leukocyte imbalances in mucopolysaccharidoses patients. Biomedicines. 2023;11(6):1699. https:\/\/doi.org\/10.3390\/biomedicines11061699.","DOI":"10.3390\/biomedicines11061699"},{"issue":"3","key":"645_CR99","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1021\/cb800277n","volume":"4","author":"N Yin","year":"2009","unstructured":"Yin N, Long X, Goff RD, Zhou D, Cantu C 3rd, Mattner J, et al. Alpha anomers of iGb3 and Gb3 stimulate cytokine production by natural killer T cells. ACS Chem Biol. 2009;4(3):199\u2013208. https:\/\/doi.org\/10.1021\/cb800277n.","journal-title":"ACS Chem Biol"},{"issue":"5","key":"645_CR100","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1084\/jem.20011786","volume":"195","author":"JE Gumperz","year":"2002","unstructured":"Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2002;195(5):625\u201336. https:\/\/doi.org\/10.1084\/jem.20011786.","journal-title":"J Exp Med"},{"issue":"1","key":"645_CR101","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","volume":"109","author":"PN De Francesco","year":"2013","unstructured":"\u2022 De Francesco PN, Mucci JM, Ceci R, Fossati CA, Rozenfeld PA. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab. 2013;109(1):93\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2013.02.003. (PBMCs from Fabry patients exhibit heightened proinflammatory cytokine levels, influenced by Gb3 accumulation and TLR4 activity.)","journal-title":"Mol Genet Metab"},{"issue":"14","key":"645_CR102","doi-asserted-by":"publisher","first-page":"7688","DOI":"10.3390\/ijms22147688","volume":"22","author":"P Li","year":"2021","unstructured":"Li P, Chang M. Roles of PRR-mediated signaling pathways in the regulation of oxidative stress and inflammatory diseases. Int J Mol Sci. 2021;22(14):7688. https:\/\/doi.org\/10.3390\/ijms22147688.","journal-title":"Int J Mol Sci."},{"issue":"9","key":"645_CR103","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/s0891-5849(00)00218-5","volume":"28","author":"YM Janssen-Heininger","year":"2000","unstructured":"Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radical Biol Med. 2000;28(9):1317\u201327. https:\/\/doi.org\/10.1016\/s0891-5849(00)00218-5.","journal-title":"Free Radical Biol Med"},{"issue":"4","key":"645_CR104","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.4049\/jimmunol.172.4.2522","volume":"172","author":"K Asehnoune","year":"2004","unstructured":"Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E. Involvement of reactive oxygen species in toll-like receptor 4-dependent activation of NF-kappa B. J Immunol. 2004;172(4):2522\u20139. https:\/\/doi.org\/10.4049\/jimmunol.172.4.2522.","journal-title":"J Immunol."},{"issue":"2","key":"645_CR105","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.ymgme.2013.12.199","volume":"111","author":"MK Pandey","year":"2014","unstructured":"Pandey MK, Tinch SL, Jabre NA, Grabowski GA. Gaucher disease: glucosylceramide-mediated TLR4-MyD88 induction causes enhanced CXCL-13 secretion and increased B cell trafficking in a mouse model. Mol Genet Metab. 2014;111(2):S84.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"645_CR106","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1523\/jneurosci.5282-06.2007","volume":"27","author":"M Suzuki","year":"2007","unstructured":"Suzuki M, Sugimoto Y, Ohsaki Y, Ueno M, Kato S, Kitamura Y, et al. Endosomal accumulation of Toll-like receptor 4 causes constitutive secretion of cytokines and activation of signal transducers and activators of transcription in Niemann-Pick disease type C (NPC) fibroblasts: a potential basis for glial cell activation in the NPC brain. J Neurosci. 2007;27(8):1879\u201391. https:\/\/doi.org\/10.1523\/jneurosci.5282-06.2007.","journal-title":"J Neurosci"},{"issue":"5","key":"645_CR107","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/hr.2010.270","volume":"34","author":"R Eissler","year":"2011","unstructured":"Eissler R, Schmaderer C, Rusai K, K\u00fchne L, Sollinger D, Lahmer T, et al. Hypertension augments cardiac toll-like receptor 4 expression and activity. Hypertens Res. 2011;34(5):551\u20138. https:\/\/doi.org\/10.1038\/hr.2010.270.","journal-title":"Hypertens Res"},{"key":"645_CR108","doi-asserted-by":"publisher","first-page":"1074700","DOI":"10.3389\/fcvm.2023.1074700","volume":"10","author":"D Theobald","year":"2023","unstructured":"Theobald D, Nair AR, Sriramula S, Francis J. Cardiomyocyte-specific deletion of TLR4 attenuates angiotensin II-induced hypertension and cardiac remodeling. Front Cardiovasc Med. 2023;10:1074700. https:\/\/doi.org\/10.3389\/fcvm.2023.1074700.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"645_CR109","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000520699","volume":"146","author":"MT Dincer","year":"2022","unstructured":"Dincer MT, Ozcan SG, Ikitimur B, Kiykim E, Bakir A, Trabulus S, et al. Blood pressure variability in Fabry disease patients. Nephron. 2022;146(4):343\u201350. https:\/\/doi.org\/10.1159\/000520699.","journal-title":"Nephron"},{"issue":"8","key":"645_CR110","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","volume":"19","author":"J Kleinert","year":"2006","unstructured":"Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, et al. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens. 2006;19(8):782\u20137. https:\/\/doi.org\/10.1016\/j.amjhyper.2006.01.011.","journal-title":"Am J Hypertens"},{"issue":"439","key":"645_CR111","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1651-2227.2002.tb03108.x","volume":"91","author":"MJ Hilz","year":"2002","unstructured":"Hilz MJ. Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr. 2002;91(439):38\u201342. https:\/\/doi.org\/10.1111\/j.1651-2227.2002.tb03108.x.","journal-title":"Acta Paediatr."},{"key":"645_CR112","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1471-2369-15-72","volume":"15","author":"S Waldek","year":"2014","unstructured":"Waldek S, Feriozzi S. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy? BMC Nephrol. 2014;15:72. https:\/\/doi.org\/10.1186\/1471-2369-15-72.","journal-title":"BMC Nephrol"},{"issue":"2","key":"645_CR113","doi-asserted-by":"publisher","first-page":"H137","DOI":"10.1152\/ajpheart.00618.2015","volume":"310","author":"MC Chappell","year":"2016","unstructured":"Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol. 2016;310(2):H137\u201352. https:\/\/doi.org\/10.1152\/ajpheart.00618.2015.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"645_CR114","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","volume":"264","author":"F Fyhrquist","year":"2008","unstructured":"Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264(3):224\u201336. https:\/\/doi.org\/10.1111\/j.1365-2796.2008.01981.x.","journal-title":"J Intern Med"},{"key":"645_CR115","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.phrs.2017.03.017","volume":"120","author":"VC Biancardi","year":"2017","unstructured":"Biancardi VC, Bomfim GF, Reis WL, Al-Gassimi S, Nunes KP. The interplay between angiotensin II, TLR4 and hypertension. Pharmacol Res. 2017;120:88\u201396. https:\/\/doi.org\/10.1016\/j.phrs.2017.03.017.","journal-title":"Pharmacol Res"},{"issue":"6","key":"645_CR116","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1161\/hy1201.100589","volume":"38","author":"M Ruiz-Ortega","year":"2001","unstructured":"Ruiz-Ortega M, Lorenzo O, Rup\u00e9rez M, Esteban V, Suzuki Y, Mezzano S, et al. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension. 2001;38(6):1382\u20137. https:\/\/doi.org\/10.1161\/hy1201.100589.","journal-title":"Hypertension."},{"issue":"3","key":"645_CR117","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s12020-021-02918-4","volume":"75","author":"C Bothou","year":"2022","unstructured":"Bothou C, Beuschlein F, Nowak A. Endocrine disorders in patients with Fabry disease: insights from a reference centre prospective study. Endocrine. 2022;75(3):728\u201339. https:\/\/doi.org\/10.1007\/s12020-021-02918-4.","journal-title":"Endocrine"},{"issue":"3","key":"645_CR118","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1157\/13100224","volume":"207","author":"B Pag\u00e1n Mu\u00f1oz","year":"2007","unstructured":"Pag\u00e1n Mu\u00f1oz B, L\u00f3pez-Rodr\u00edguez M, G\u00f3mez Cerezo JF, Poyatos Toribio C, Barbado Hern\u00e1ndez FJ. Effect of renin-angiotensin system in Fabry disease associated proteinuria. Rev Clin Esp. 2007;207(3):125\u20138. https:\/\/doi.org\/10.1157\/13100224.","journal-title":"Rev Clin Esp"},{"issue":"4","key":"645_CR119","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1159\/000490866","volume":"47","author":"Q Su","year":"2018","unstructured":"Su Q, Li L, Sun Y, Yang H, Ye Z, Zhao J. Effects of the TLR4\/Myd88\/NF-\u03baB signaling pathway on NLRP3 inflammasome in coronary microembolization-induced myocardial injury. Cell Physiol Biochem. 2018;47(4):1497\u2013508. https:\/\/doi.org\/10.1159\/000490866.","journal-title":"Cell Physiol Biochem"},{"issue":"6","key":"645_CR120","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1007\/s10753-022-01707-z","volume":"45","author":"JA Espitia-Corredor","year":"2022","unstructured":"Espitia-Corredor JA, Boza P, Espinoza-P\u00e9rez C, Lillo JM, Rimassa-Tar\u00e9 C, Machuca V, et al. Angiotensin II triggers NLRP3 inflammasome activation by a Ca(2+) signaling-dependent pathway in rat cardiac fibroblast Ang-II by a Ca(2+)-dependent mechanism triggers NLRP3 inflammasome in CF. Inflammation. 2022;45(6):2498\u2013512. https:\/\/doi.org\/10.1007\/s10753-022-01707-z.","journal-title":"Inflammation"},{"key":"645_CR121","doi-asserted-by":"publisher","first-page":"5867987","DOI":"10.1155\/2022\/5867987","volume":"2022","author":"X Zhang","year":"2022","unstructured":"Zhang X, Qu H, Yang T, Liu Q, Zhao D, Liu W, et al. LuQi formula ameliorates myocardial fibrosis by suppressing TLR4\/MyD88\/NF-\u03baB pathway and NLRP3 inflammasome activation in mice with myocardial infarction. Evidence-based Complement Alternat Med: eCAM. 2022;2022:5867987. https:\/\/doi.org\/10.1155\/2022\/5867987.","journal-title":"Evidence-based Complement Alternat Med: eCAM"},{"issue":"7","key":"645_CR122","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00210-023-02409-5","volume":"396","author":"J Hu","year":"2023","unstructured":"Hu J, Xu J, Tan X, Li D, Yao D, Xu B, et al. Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2023;396(7):1461\u201370. https:\/\/doi.org\/10.1007\/s00210-023-02409-5.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"645_CR123","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cophys.2020.10.003","volume":"19","author":"VK Ninh","year":"2021","unstructured":"Ninh VK, Brown JH. The contribution of the cardiomyocyte to tissue inflammation in cardiomyopathies. Curr Opin Physio. 2021;19:129\u201334. https:\/\/doi.org\/10.1016\/j.cophys.2020.10.003.","journal-title":"Curr Opin Physio"},{"issue":"14","key":"645_CR124","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1113\/jp276758","volume":"598","author":"A Colliva","year":"2020","unstructured":"Colliva A, Braga L, Giacca M, Zacchigna S. Endothelial cell-cardiomyocyte crosstalk in heart development and disease. J Physiol. 2020;598(14):2923\u201339. https:\/\/doi.org\/10.1113\/jp276758.","journal-title":"J Physiol"},{"key":"645_CR125","doi-asserted-by":"publisher","first-page":"882027","DOI":"10.3389\/fcvm.2022.882027","volume":"9","author":"Y Xuan","year":"2022","unstructured":"Xuan Y, Chen C, Wen Z, Wang DW. The roles of cardiac fibroblasts and endothelial cells in myocarditis. Front Cardiovas Med. 2022;9:882027. https:\/\/doi.org\/10.3389\/fcvm.2022.882027.","journal-title":"Front Cardiovas Med"},{"issue":"16","key":"645_CR126","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3390\/cells12162102","volume":"12","author":"MM Ivanova","year":"2023","unstructured":"Ivanova MM, Dao J, Slayeh OA, Friedman A, Goker-Alpan O. Circulated TGF-\u03b21 and VEGF-A as biomarkers for Fabry disease-associated cardiomyopathy. Cells. 2023;12(16):2102. https:\/\/doi.org\/10.3390\/cells12162102.","journal-title":"Cells."},{"issue":"2","key":"645_CR127","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199\u2013210. https:\/\/doi.org\/10.1002\/path.2277.","journal-title":"J Pathol"},{"key":"645_CR128","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ijcard.2017.06.079","volume":"248","author":"A Frustaci","year":"2017","unstructured":"Frustaci A, Chimenti C, Doheny D, Desnick RJ. Evolution of cardiac pathology in classic Fabry disease: progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy. Int J Cardiol. 2017;248:257\u201362. https:\/\/doi.org\/10.1016\/j.ijcard.2017.06.079.","journal-title":"Int J Cardiol"},{"issue":"4","key":"645_CR129","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1161\/circulationaha.108.794529","volume":"119","author":"F Weidemann","year":"2009","unstructured":"Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, St\u00f6rk S, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119(4):524\u20139. https:\/\/doi.org\/10.1161\/circulationaha.108.794529.","journal-title":"Circulation"},{"issue":"15","key":"645_CR130","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.3390\/diagnostics13152598","volume":"13","author":"A Ponsiglione","year":"2023","unstructured":"Ponsiglione A, De Giorgi M, Ascione R, Nappi C, Sanduzzi L, Pisani A, et al. Advanced CMR techniques in Anderson-Fabry disease: state of the art. Diagnostics. 2023;13(15):2598. https:\/\/doi.org\/10.3390\/diagnostics13152598.","journal-title":"Diagnostics."},{"issue":"1","key":"645_CR131","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/circgenetics.113.000249","volume":"7","author":"M Niemann","year":"2014","unstructured":"Niemann M, Rolfs A, St\u00f6rk S, Bijnens B, Breunig F, Beer M, et al. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014;7(1):8\u201316. https:\/\/doi.org\/10.1161\/circgenetics.113.000249.","journal-title":"Circ Cardiovasc Genet"},{"issue":"2","key":"645_CR132","doi-asserted-by":"publisher","first-page":"e000803","DOI":"10.1136\/openhrt-2018-000803","volume":"5","author":"D Liu","year":"2018","unstructured":"Liu D, Oder D, Salinger T, Hu K, M\u00fcntze J, Weidemann F, et al. Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease. Open heart. 2018;5(2):e000803. https:\/\/doi.org\/10.1136\/openhrt-2018-000803.","journal-title":"Open heart"},{"key":"645_CR133","doi-asserted-by":"publisher","unstructured":"Aguiar P, Azevedo O, Pinto R, Marino J, Cardoso C, Sousa N, et al. Biomarkers of myocardial fibrosis: revealing the natural history of fibrogenesis in Fabry disease cardiomyopathy. J Amer Heart Assoc. 2018;7(6):e007124. https:\/\/doi.org\/10.1161\/JAHA.117.007124.","DOI":"10.1161\/JAHA.117.007124"},{"issue":"6","key":"645_CR134","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","volume":"4","author":"M Niemann","year":"2011","unstructured":"\u2022 Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4(6):592\u2013601. https:\/\/doi.org\/10.1016\/j.jcmg.2011.01.020. (Female Fabry disease patients can develop fibrosis and myocardial dysfunction without hypertrophy, differing from standard male progression.)","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"645_CR135","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1002\/ajmg.a.62728","volume":"188","author":"M \u0158eboun","year":"2022","unstructured":"\u0158eboun M, Sikora J, Magner M, Wiederlechnerov\u00e1 H, \u010cern\u00e1 A, Poup\u011btov\u00e1 H, et al. Pitfalls of X-chromosome inactivation testing in females with Fabry disease. Am J Med Genet A. 2022;188(7):1979\u201389. https:\/\/doi.org\/10.1002\/ajmg.a.62728.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"645_CR136","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.gene.2012.06.013","volume":"505","author":"D Elstein","year":"2012","unstructured":"Elstein D, Schachamorov E, Beeri R, Altarescu G. X-inactivation in Fabry disease. Gene. 2012;505(2):266\u20138. https:\/\/doi.org\/10.1016\/j.gene.2012.06.013.","journal-title":"Gene"},{"issue":"9","key":"645_CR137","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.3390\/ijms22094514","volume":"22","author":"P Juchniewicz","year":"2021","unstructured":"Juchniewicz P, Piotrowska E, Kloska A, Podlacha M, Mantej J, W\u0119grzyn G, et al. Dosage compensation in females with X-linked metabolic disorders. Int J Mol Sci. 2021;22(9):4514. https:\/\/doi.org\/10.3390\/ijms22094514.","journal-title":"Int J Mol Sci."},{"issue":"8","key":"645_CR138","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/jmg.33.8.682","volume":"33","author":"I Redonnet-Vernhet","year":"1996","unstructured":"Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Gen. 1996;33(8):682\u20138. https:\/\/doi.org\/10.1136\/jmg.33.8.682.","journal-title":"J Med Gen."},{"issue":"8","key":"645_CR139","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1136\/jmg.40.8.e103","volume":"40","author":"A Morrone","year":"2003","unstructured":"Morrone A, Cavicchi C, Bardelli T, Antuzzi D, Parini R, Di Rocco M, et al. Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers. J Med Genet. 2003;40(8):e103. https:\/\/doi.org\/10.1136\/jmg.40.8.e103.","journal-title":"J Med Genet"},{"issue":"8","key":"645_CR140","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","volume":"83","author":"R Dobrovolny","year":"2005","unstructured":"Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, Lubanda JC, et al. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med. 2005;83(8):647\u201354. https:\/\/doi.org\/10.1007\/s00109-005-0656-2.","journal-title":"J Mol Med."},{"issue":"1","key":"645_CR141","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89(1):44\u201354. https:\/\/doi.org\/10.1111\/cge.12613.","journal-title":"Clin Genet"},{"issue":"14","key":"645_CR142","doi-asserted-by":"publisher","first-page":"7663","DOI":"10.3390\/ijms22147663","volume":"22","author":"E Viggiano","year":"2021","unstructured":"Viggiano E, Politano L. X chromosome inactivation in carriers of Fabry disease: review and meta-analysis. Int J Mol Sci. 2021;22(14):7663. https:\/\/doi.org\/10.3390\/ijms22147663.","journal-title":"Int J Mol Sci."},{"issue":"451","key":"645_CR143","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/08035320600618809","volume":"95","author":"EM Maier","year":"2006","unstructured":"Maier EM, Osterrieder S, Whybra C, Ries M, Gal A, Beck M, et al. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr. 2006;95(451):30\u20138. https:\/\/doi.org\/10.1080\/08035320600618809.","journal-title":"Acta Paediatr."},{"issue":"5","key":"645_CR144","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.3892\/etm.2017.4246","volume":"13","author":"G Liu","year":"2017","unstructured":"Liu G, Ma C, Yang H, Zhang PY. Transforming growth factor \u03b2 and its role in heart disease. Exp Ther Med. 2017;13(5):2123\u20138. https:\/\/doi.org\/10.3892\/etm.2017.4246.","journal-title":"Exp Ther Med"},{"issue":"2","key":"645_CR145","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4274\/jpr.galenos.2018.21548","volume":"6","author":"E Canda","year":"2019","unstructured":"Canda E, K\u00f6se M, Ka\u011fn\u0131c\u0131 M, Dondurmac\u0131 M, U\u00e7ar SK, S\u00f6zmen E, et al. Evaluation of cardiovascular involvement and cytokine levels in patients with mucopolysaccharidosis. J Pediatr Res. 2019;6(2):121\u20137.","journal-title":"J Pediatr Res."},{"issue":"16","key":"645_CR146","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/s0025-7753(00)71637-x","volume":"115","author":"JI P\u00e9rez Calvo","year":"2000","unstructured":"P\u00e9rez Calvo JI, I\u00f1igo Gil P, GiraldoCastellano P, TorralbaCabeza MA, Civeira F, LarioGarc\u00eda S, et al. Transforming growth factor beta (TGF-beta) in Gaucher\u2019s disease. Preliminary results in a group of patients and their carrier and non-carrier relatives. Med Clin. 2000;115(16):601\u20134. https:\/\/doi.org\/10.1016\/s0025-7753(00)71637-x.","journal-title":"Med Clin."},{"issue":"2","key":"645_CR147","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cardiores.2006.10.002","volume":"74","author":"M Bujak","year":"2007","unstructured":"Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74(2):184\u201395. https:\/\/doi.org\/10.1016\/j.cardiores.2006.10.002.","journal-title":"Cardiovasc Res"},{"key":"645_CR148","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cellsig.2018.09.002","volume":"52","author":"A Vander Ark","year":"2018","unstructured":"Vander Ark A, Cao J, Li X. TGF-\u03b2 receptors: in and beyond TGF-\u03b2 signaling. Cell Signal. 2018;52:112\u201320. https:\/\/doi.org\/10.1016\/j.cellsig.2018.09.002.","journal-title":"Cell Signal"},{"issue":"5","key":"645_CR149","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08977194.2011.595714","volume":"29","author":"A Biernacka","year":"2011","unstructured":"Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-\u03b2 signaling in fibrosis. Growth Factors. 2011;29(5):196\u2013202. https:\/\/doi.org\/10.3109\/08977194.2011.595714.","journal-title":"Growth Factors"},{"issue":"4","key":"645_CR150","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","volume":"51","author":"M Dobaczewski","year":"2011","unstructured":"Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-\u03b2 signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51(4):600\u20136. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.10.033.","journal-title":"J Mol Cell Cardiol"},{"key":"645_CR151","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/8904_2012_141","volume":"7","author":"S Yano","year":"2013","unstructured":"Yano S, Li C, Pavlova Z. The transforming growth factor-beta signaling pathway involvement in cardiovascular lesions in mucopolysaccharidosis-I. JIMD Rep. 2013;7:55\u20138. https:\/\/doi.org\/10.1007\/8904_2012_141.","journal-title":"JIMD Rep"},{"issue":"15","key":"645_CR152","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1182\/blood-2009-02-205708","volume":"114","author":"PM Campeau","year":"2009","unstructured":"Campeau PM, Rafei M, Boivin MN, Sun Y, Grabowski GA, Galipeau J. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood. 2009;114(15):3181\u201390. https:\/\/doi.org\/10.1182\/blood-2009-02-205708.","journal-title":"Blood"},{"issue":"6","key":"645_CR153","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","volume":"26","author":"MD Sanchez-Ni\u00f1o","year":"2011","unstructured":"Sanchez-Ni\u00f1o MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Trans. 2011;26(6):1797\u2013802. https:\/\/doi.org\/10.1093\/ndt\/gfq306.","journal-title":"Nephrol Dial Trans"},{"issue":"2","key":"645_CR154","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ymgme.2019.10.010","volume":"129","author":"PA Rozenfeld","year":"2020","unstructured":"Rozenfeld PA, de Los Angeles Bolla M, Quieto P, Pisani A, Feriozzi S, Neuman P, et al. Pathogenesis of Fabry nephropathy: the pathways leading to fibrosis. Mol Gen Metab. 2020;129(2):132\u201341. https:\/\/doi.org\/10.1016\/j.ymgme.2019.10.010.","journal-title":"Mol Gen Metab."},{"issue":"6","key":"645_CR155","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","volume":"30","author":"MH Lee","year":"2012","unstructured":"Lee MH, Choi EN, Jeon YJ, Jung SC. Possible role of transforming growth factor-\u03b21 and vascular endothelial growth factor in Fabry disease nephropathy. Int J Mol Med. 2012;30(6):1275\u201380. https:\/\/doi.org\/10.3892\/ijmm.2012.1139.","journal-title":"Int J Mol Med"},{"issue":"4","key":"645_CR156","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.bbrc.2015.11.050","volume":"468","author":"JY Choi","year":"2015","unstructured":"Choi JY, Shin MY, Suh SH, Park S. Lyso-globotriaosylceramide downregulates KCa3.1 channel expression to inhibit collagen synthesis in fibroblasts. Biochem Biophys Res Commun. 2015;468(4):883\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2015.11.050.","journal-title":"Biochem Biophys Res Commun."},{"issue":"5","key":"645_CR157","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1161\/01.HYP.0000144400.49062.6b","volume":"44","author":"K Chen","year":"2004","unstructured":"Chen K, Chen J, Li D, Zhang X, Mehta JL. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension. 2004;44(5):655\u201361. https:\/\/doi.org\/10.1161\/01.HYP.0000144400.49062.6b.","journal-title":"Hypertension."},{"key":"645_CR158","doi-asserted-by":"publisher","unstructured":"Laurino A, Spinelli V, Gencarelli M, Balducci V, Dini L, Diolaiuti L, et al. Angiotensin-II drives human satellite cells toward hypertrophy and myofibroblast trans-differentiation by two independent pathways. Int J Mol Sci. 2019;20(19):4912. https:\/\/doi.org\/10.3390\/ijms20194912.","DOI":"10.3390\/ijms20194912"},{"issue":"10","key":"645_CR159","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1161\/01.cir.101.10.1130","volume":"101","author":"H Kawano","year":"2000","unstructured":"Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE, et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation. 2000;101(10):1130\u20137. https:\/\/doi.org\/10.1161\/01.cir.101.10.1130.","journal-title":"Circulation"},{"issue":"9","key":"645_CR160","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/abbs\/gmy090","volume":"50","author":"L Cao","year":"2018","unstructured":"Cao L, Chen Y, Lu L, Liu Y, Wang Y, Fan J, et al. Angiotensin II upregulates fibroblast-myofibroblast transition through Cx43-dependent CaMKII and TGF-\u03b21 signaling in neonatal rat cardiac fibroblasts. Acta Biochim Biophys Sin. 2018;50(9):843\u201352. https:\/\/doi.org\/10.1093\/abbs\/gmy090.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"1","key":"645_CR161","doi-asserted-by":"publisher","first-page":"e010418","DOI":"10.1161\/jaha.118.010418","volume":"8","author":"G She","year":"2019","unstructured":"She G, Ren YJ, Wang Y, Hou MC, Wang HF, Gou W, et al. K(Ca)3.1 channels promote cardiac fibrosis through mediating inflammation and differentiation of monocytes into myofibroblasts in angiotensin II -treated rats. J Amer Heart Assoc. 2019;8(1):e010418. https:\/\/doi.org\/10.1161\/jaha.118.010418.","journal-title":"J Amer Heart Assoc."},{"issue":"1","key":"645_CR162","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2741\/3923","volume":"17","author":"L Jia","year":"2012","unstructured":"Jia L, Li Y, Xiao C, Du J. Angiotensin II induces inflammation leading to cardiac remodeling. Front Biosci. 2012;17(1):221\u201331. https:\/\/doi.org\/10.2741\/3923.","journal-title":"Front Biosci"},{"issue":"4","key":"645_CR163","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/labinvest.2010.190","volume":"91","author":"MJ Sopel","year":"2011","unstructured":"Sopel MJ, Rosin NL, Lee TD, L\u00e9gar\u00e9 JF. Myocardial fibrosis in response to angiotensin II is preceded by the recruitment of mesenchymal progenitor cells. Lab Investig: J Tech Methods Pathol. 2011;91(4):565\u201378. https:\/\/doi.org\/10.1038\/labinvest.2010.190.","journal-title":"Lab Investig: J Tech Methods Pathol."},{"issue":"1","key":"645_CR164","doi-asserted-by":"publisher","first-page":"L1","DOI":"10.1152\/ajplung.00378.2006","volume":"293","author":"E Arciniegas","year":"2007","unstructured":"Arciniegas E, Frid MG, Douglas IS, Stenmark KR. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;293(1):L1-8. https:\/\/doi.org\/10.1152\/ajplung.00378.2006.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"11","key":"645_CR165","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00228-020-02919-8","volume":"76","author":"A Akbari","year":"2020","unstructured":"Akbari A, Mobini GR, Agah S, Morvaridzadeh M, Omidi A, Potter E, et al. Coenzyme Q10 supplementation and oxidative stress parameters: a systematic review and meta-analysis of clinical trials. Eur J Clin Pharmacol. 2020;76(11):1483\u201399. https:\/\/doi.org\/10.1007\/s00228-020-02919-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"645_CR166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0574-8","volume":"12","author":"M de la Mata","year":"2017","unstructured":"de la Mata M, Cot\u00e1n D, Oropesa-\u00c1vila M, Villanueva-Paz M, de Lavera I, \u00c1lvarez-C\u00f3rdoba M, et al. Coenzyme Q10 partially restores pathological alterations in a macrophage model of Gaucher disease. Orphanet J Rare Dis. 2017;12(1):1\u201315.","journal-title":"Orphanet J Rare Dis."},{"issue":"2","key":"645_CR167","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11011-022-01128-9","volume":"38","author":"TG Hammerschmidt","year":"2023","unstructured":"Hammerschmidt TG, Donida B, Raabe M, Faverzani JL, de F\u00e1tima LF, Machado AZ, et al. Evidence of redox imbalance and mitochondrial dysfunction in Niemann-Pick type C 1 patients: the in vitro effect of combined therapy with antioxidants and \u03b2-cyclodextrin nanoparticles. Metab Brain Dis. 2023;38(2):507\u201318. https:\/\/doi.org\/10.1007\/s11011-022-01128-9.","journal-title":"Metab Brain Dis"},{"issue":"9","key":"645_CR168","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.bbabio.2018.04.006","volume":"1859","author":"V Giorgio","year":"2018","unstructured":"Giorgio V, Schiavone M, Galber C, Carini M, Da Ros T, Petronilli V, et al. The idebenone metabolite QS10 restores electron transfer in complex I and coenzyme Q defects. Biochim Biophys Acta. 2018;1859(9):901\u20138. https:\/\/doi.org\/10.1016\/j.bbabio.2018.04.006.","journal-title":"Biochim Biophys Acta"},{"issue":"23","key":"645_CR169","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1093\/hmg\/ddv369","volume":"24","author":"M Keatinge","year":"2015","unstructured":"Keatinge M, Bui H, Menke A, Chen YC, Sokol AM, Bai Q, et al. Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. Hum Mol Genet. 2015;24(23):6640\u201352. https:\/\/doi.org\/10.1093\/hmg\/ddv369.","journal-title":"Hum Mol Genet"},{"key":"645_CR170","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1038\/ncomms5028","volume":"5","author":"DC Sch\u00f6ndorf","year":"2014","unstructured":"Sch\u00f6ndorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, et al. iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun. 2014;5:4028. https:\/\/doi.org\/10.1038\/ncomms5028.","journal-title":"Nat Commun"},{"issue":"1","key":"645_CR171","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ymgme.2011.10.009","volume":"105","author":"GM Enns","year":"2012","unstructured":"Enns GM, Kinsman SL, Perlman SL, Spicer KM, Abdenur JE, Cohen BH, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab. 2012;105(1):91\u2013102. https:\/\/doi.org\/10.1016\/j.ymgme.2011.10.009.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"645_CR172","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ymgme.2013.03.011","volume":"109","author":"A Pastore","year":"2013","unstructured":"Pastore A, Petrillo S, Tozzi G, Carrozzo R, Martinelli D, Dionisi-Vici C, et al. Glutathione: a redox signature in monitoring EPI-743 therapy in children with mitochondrial encephalomyopathies. Mol Genet Metab. 2013;109(2):208\u201314. https:\/\/doi.org\/10.1016\/j.ymgme.2013.03.011.","journal-title":"Mol Genet Metab"},{"key":"645_CR173","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.redox.2016.11.010","volume":"11","author":"S Torres","year":"2017","unstructured":"Torres S, Mat\u00edas N, Baulies A, Nu\u00f1ez S, Alarcon-Vila C, Martinez L, et al. Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease. Redox Biol. 2017;11:60\u201372. https:\/\/doi.org\/10.1016\/j.redox.2016.11.010.","journal-title":"Redox Biol"},{"issue":"1","key":"645_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/1678-4685-gmb-2017-0334","volume":"42","author":"JA Oliveira-Silva","year":"2019","unstructured":"Oliveira-Silva JA, Yamamoto JUP, Oliveira RB, Monteiro VCL, Frangipani BJ, Kyosen SO, et al. Oxidative stress assessment by glutathione peroxidase activity and glutathione levels in response to selenium supplementation in patients with mucopolysaccharidosis I, II and VI. Genet Mol Biol. 2019;42(1):1\u20138. https:\/\/doi.org\/10.1590\/1678-4685-gmb-2017-0334.","journal-title":"Genet Mol Biol"},{"key":"645_CR175","doi-asserted-by":"publisher","unstructured":"Daubert MA, Yow E, Dunn G, Marchev S, Barnhart H, Douglas PS, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail.\u00a0 2017;10(12):e004389. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004389.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004389"},{"issue":"3","key":"645_CR176","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41436-020-01006-8","volume":"23","author":"W Reid Thompson","year":"2021","unstructured":"Reid Thompson W, Hornby B, Manuel R, Bradley E, Laux J, Carr J, et al. A phase 2\/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Gen Med. 2021;23(3):471\u20138. https:\/\/doi.org\/10.1038\/s41436-020-01006-8.","journal-title":"Gen Med"},{"key":"645_CR177","doi-asserted-by":"publisher","unstructured":"Fetisova E, Chernyak B, Korshunova G, Muntyan M, Skulachev VJCMC. Mitochondria-targeted antioxidants as a prospective therapeutic strategy for multiple sclerosis. Curr Med Chem. 2017;24(19):2086\u2013114.\u00a0https:\/\/doi.org\/10.2174\/0929867324666170316114452.","DOI":"10.2174\/0929867324666170316114452"},{"issue":"1","key":"645_CR178","doi-asserted-by":"publisher","first-page":"15862","DOI":"10.1038\/s41598-018-34251-8","volume":"8","author":"I Escribano-Lopez","year":"2018","unstructured":"Escribano-Lopez I, Diaz-Morales N, Iannantuoni F, Lopez-Domenech S, de Mara\u00f1on AM, Abad-Jimenez Z, et al. The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes. Sci Rep. 2018;8(1):15862. https:\/\/doi.org\/10.1038\/s41598-018-34251-8.","journal-title":"Sci Rep"},{"issue":"4","key":"645_CR179","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/jcsm.12559","volume":"11","author":"A Karaa","year":"2020","unstructured":"Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11(4):909\u201318. https:\/\/doi.org\/10.1002\/jcsm.12559.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"645_CR180","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1212\/wnl.0000000000207402","volume":"101","author":"A Karaa","year":"2023","unstructured":"Karaa A, Bertini E, Carelli V, Cohen BH, Enns GM, Falk MJ, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238\u201352. https:\/\/doi.org\/10.1212\/wnl.0000000000207402.","journal-title":"Neurology"},{"issue":"1","key":"645_CR181","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/jmd2.12335","volume":"64","author":"MK Koenig","year":"2023","unstructured":"Koenig MK, Russo SN, McBride KL, Bjornsson HT, Gunnarsdottir BB, Goldstein A, et al. Use of Elamipretide in patients assigned treatment in the compassionate use program: case series in pediatric patients with rare orphan diseases. JIMD Rep. 2023;64(1):65\u201370. https:\/\/doi.org\/10.1002\/jmd2.12335.","journal-title":"JIMD Rep"},{"issue":"8","key":"645_CR182","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/bph.12461","volume":"171","author":"HH Szeto","year":"2014","unstructured":"Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029\u201350. https:\/\/doi.org\/10.1111\/bph.12461.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"645_CR183","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/clpt.2014.174","volume":"96","author":"H Szeto","year":"2014","unstructured":"Szeto H, Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther. 2014;96(6):672\u201383.","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"645_CR184","doi-asserted-by":"publisher","first-page":"21240","DOI":"10.1074\/jbc.M300339200","volume":"278","author":"EM Ciszak","year":"2003","unstructured":"Ciszak EM, Korotchkina LG, Dominiak PM, Sidhu S, Patel MS. Structural basis for flip-flop action of thiamin pyrophosphate-dependent enzymes revealed by human pyruvate dehydrogenase. J Biol Chem. 2003;278(23):21240\u20136. https:\/\/doi.org\/10.1074\/jbc.M300339200.","journal-title":"J Biol Chem"},{"issue":"9","key":"645_CR185","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.bbabio.2018.05.005","volume":"1859","author":"GV Mkrtchyan","year":"2018","unstructured":"Mkrtchyan GV, \u00dc\u00e7al M, M\u00fcllebner A, Dumitrescu S, Kames M, Moldzio R, et al. Thiamine preserves mitochondrial function in a rat model of traumatic brain injury, preventing inactivation of the 2-oxoglutarate dehydrogenase complex. Biochim Biophys Acta. 2018;1859(9):925\u201331. https:\/\/doi.org\/10.1016\/j.bbabio.2018.05.005.","journal-title":"Biochim Biophys Acta"},{"key":"645_CR186","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.resuscitation.2016.04.024","volume":"105","author":"K Ikeda","year":"2016","unstructured":"Ikeda K, Liu X, Kida K, Marutani E, Hirai S, Sakaguchi M, et al. Thiamine as a neuroprotective agent after cardiac arrest. Resuscitation. 2016;105:138\u201344. https:\/\/doi.org\/10.1016\/j.resuscitation.2016.04.024.","journal-title":"Resuscitation"},{"issue":"3","key":"645_CR187","doi-asserted-by":"publisher","first-page":"106074","DOI":"10.1016\/j.isci.2023.106074","volume":"26","author":"J Gambardella","year":"2023","unstructured":"Gambardella J, Fiordelisi A, Cerasuolo FA, Buonaiuto A, Avvisato R, Viti A, et al. Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease. iScience. 2023;26(3):106074. https:\/\/doi.org\/10.1016\/j.isci.2023.106074.","journal-title":"iScience."},{"issue":"5930","key":"645_CR188","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029\u201333. https:\/\/doi.org\/10.1126\/science.1160809.","journal-title":"Science"},{"issue":"7","key":"645_CR189","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1089\/ars.2012.5149","volume":"20","author":"M Mittal","year":"2014","unstructured":"Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20(7):1126\u201367. https:\/\/doi.org\/10.1089\/ars.2012.5149.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"645_CR190","first-page":"70","volume":"9","author":"A Al-Shukaili","year":"2009","unstructured":"Al-Shukaili A, Al-Abri S, Al-Ansari A, Monteil MA. Effect of N-acetyl-L-cysteine on cytokine production by human peripheral blood mononuclear cells. Sultan Qaboos Univ Med J. 2009;9(1):70\u20134.","journal-title":"Sultan Qaboos Univ Med J"},{"issue":"4","key":"645_CR191","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/jmri.20162","volume":"20","author":"DF Moore","year":"2004","unstructured":"Moore DF, Ye F, Brennan ML, Gupta S, Barshop BA, Steiner RD, et al. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging: JMRI. 2004;20(4):674\u201383. https:\/\/doi.org\/10.1002\/jmri.20162.","journal-title":"J Magn Reson Imaging: JMRI"},{"issue":"5","key":"645_CR192","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1399-0004.1987.tb02820.x","volume":"31","author":"H Sakuraba","year":"1987","unstructured":"Sakuraba H, Igarashi T, Shibata T, Suzuki Y. Effect of vitamin E and ticlopidine on platelet aggregation in Fabry\u2019s disease. Clin Genet. 1987;31(5):349\u201354. https:\/\/doi.org\/10.1111\/j.1399-0004.1987.tb02820.x.","journal-title":"Clin Genet"},{"issue":"9","key":"645_CR193","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Gen Med. 2006;8(9):539\u201348. https:\/\/doi.org\/10.1097\/01.gim.0000237866.70357.c6.","journal-title":"Gen Med"},{"key":"645_CR194","doi-asserted-by":"publisher","first-page":"924710","DOI":"10.3389\/fnut.2022.924710","volume":"9","author":"G Bertoldi","year":"2022","unstructured":"Bertoldi G, Carraro G, Ravarotto V, Di Vico V, Baldini Anastasio P, Vitturi N, et al. The effect of green tea as an adjuvant to enzyme replacement therapy on oxidative stress in Fabry disease: a pilot study. Front Nutr. 2022;9:924710. https:\/\/doi.org\/10.3389\/fnut.2022.924710.","journal-title":"Front Nutr"},{"issue":"1","key":"645_CR195","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12951-022-01318-8","volume":"20","author":"JH An","year":"2022","unstructured":"An JH, Hong SE, Yu SL, Kang J, Park CG, Lee HY, et al. Ceria-Zirconia nanoparticles reduce intracellular globotriaosylceramide accumulation and attenuate kidney injury by enhancing the autophagy flux in cellular and animal models of Fabry disease. J Nanobiotechnol. 2022;20(1):125. https:\/\/doi.org\/10.1186\/s12951-022-01318-8.","journal-title":"J Nanobiotechnol"},{"key":"645_CR196","doi-asserted-by":"publisher","first-page":"109106","DOI":"10.1016\/j.yebeh.2023.109106","volume":"140","author":"B Poorshiri","year":"2023","unstructured":"Poorshiri B, Barzegar M, Afghan M, Shiva S, Shahabi P, Golchinfar Z, et al. The effects of ketogenic diet on beta-hydroxybutyrate, arachidonic acid, and oxidative stress in pediatric epilepsy. Epilepsy Behav: E&B. 2023;140:109106. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109106.","journal-title":"Epilepsy Behav: E&B"},{"issue":"1","key":"645_CR197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12997\/jla.2022.11.1.1","volume":"11","author":"H Saucedo-Orozco","year":"2022","unstructured":"Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD. SGLT2 inhibitors and ketone metabolism in heart failure. J Lipid Atheroscler. 2022;11(1):1\u201319. https:\/\/doi.org\/10.12997\/jla.2022.11.1.1.","journal-title":"J Lipid Atheroscler."},{"issue":"5","key":"645_CR198","doi-asserted-by":"publisher","first-page":"e35476","DOI":"10.1371\/journal.pone.0035476","volume":"7","author":"DY Kim","year":"2012","unstructured":"Kim DY, Hao J, Liu R, Turner G, Shi FD, Rho JM. Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. PLoS ONE. 2012;7(5):e35476. https:\/\/doi.org\/10.1371\/journal.pone.0035476.","journal-title":"PLoS ONE"},{"issue":"5","key":"645_CR199","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/antiox7050063","volume":"7","author":"A Pinto","year":"2018","unstructured":"Pinto A, Bonucci A, Maggi E, Corsi M, Businaro R. Anti-oxidant and anti-inflammatory activity of ketogenic diet: new perspectives for neuroprotection in Alzheimer\u2019s disease. Antioxidants. 2018;7(5):63. https:\/\/doi.org\/10.3390\/antiox7050063.","journal-title":"Antioxidants."},{"issue":"7","key":"645_CR200","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.clnu.2022.05.007","volume":"41","author":"PM Lorenzo","year":"2022","unstructured":"Lorenzo PM, Sajoux I, Izquierdo AG, Gomez-Arbelaez D, Zulet MA, Abete I, et al. Immunomodulatory effect of a very-low-calorie ketogenic diet compared with bariatric surgery and a low-calorie diet in patients with excessive body weight. Clin Nut. 2022;41(7):1566\u201377. https:\/\/doi.org\/10.1016\/j.clnu.2022.05.007.","journal-title":"Clin Nut"},{"key":"645_CR201","doi-asserted-by":"publisher","unstructured":"Forsythe CE, Phinney SD, Fernandez ML, Quann EE, Wood RJ, Bibus DM, et al. Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. Lipids. 2008;43(1):65\u201377. https:\/\/doi.org\/10.1007\/s11745-007-3132-7.","DOI":"10.1007\/s11745-007-3132-7"},{"issue":"4","key":"645_CR202","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.18632\/aging.101838","volume":"11","author":"DH Kim","year":"2019","unstructured":"Kim DH, Park MH, Ha S, Bang EJ, Lee Y, Lee AK, et al. Anti-inflammatory action of \u03b2-hydroxybutyrate via modulation of PGC-1\u03b1 and FoxO1, mimicking calorie restriction. Aging. 2019;11(4):1283\u2013304. https:\/\/doi.org\/10.18632\/aging.101838.","journal-title":"Aging."},{"issue":"3","key":"645_CR203","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"YH Youm","year":"2015","unstructured":"Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21(3):263\u20139. https:\/\/doi.org\/10.1038\/nm.3804.","journal-title":"Nat Med"},{"key":"645_CR204","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s10571-018-0617-2","volume":"38","author":"S Shang","year":"2018","unstructured":"Shang S, Wang L, Zhang Y, Lu H, Lu XJC. The beta-hydroxybutyrate suppresses the migration of glioma cells by inhibition of NLRP3 inflammasome. Cell Mol Neurobiol. 2018;38:1479\u201389.","journal-title":"Cell Mol Neurobiol."},{"issue":"7","key":"645_CR205","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1021\/acschemneuro.1c00046","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang X, Ma A, Kang Y. Rational application of \u03b2-hydroxybutyrate attenuates ischemic stroke by suppressing oxidative stress and mitochondrial-dependent apoptosis via activation of the Erk\/CREB\/eNOS pathway. ACS Chem Neurosci. 2021;12(7):1219\u201327. https:\/\/doi.org\/10.1021\/acschemneuro.1c00046.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"645_CR206","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/cvr\/cvq333","volume":"89","author":"S Park","year":"2011","unstructured":"Park S, Kim JA, Joo KY, Choi S, Choi EN, Shin JA, et al. Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease. Cardiovas Res. 2011;89(2):290\u20139. https:\/\/doi.org\/10.1093\/cvr\/cvq333.","journal-title":"Cardiovas Res."},{"issue":"4","key":"645_CR207","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.bbrc.2016.01.152","volume":"470","author":"JY Choi","year":"2016","unstructured":"Choi JY, Park S. Role of protein kinase A and class II phosphatidylinositol 3-kinase C2\u03b2 in the downregulation of KCa3.1 channel synthesis and membrane surface expression by lyso-globotriaosylceramide. Biochem Biophys Res Commun. 2016;470(4):907\u201312. https:\/\/doi.org\/10.1016\/j.bbrc.2016.01.152.","journal-title":"Biochem Biophys Res Commun."},{"issue":"1","key":"645_CR208","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/acel.12409","volume":"15","author":"E Aflaki","year":"2016","unstructured":"Aflaki E, Moaven N, Borger DK, Lopez G, Westbroek W, Chae JJ, et al. Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages. Aging Cell. 2016;15(1):77\u201388. https:\/\/doi.org\/10.1111\/acel.12409.","journal-title":"Aging Cell"},{"key":"645_CR209","doi-asserted-by":"publisher","first-page":"104679","DOI":"10.1016\/j.yexmp.2021.104679","volume":"123","author":"\u0141 Pawli\u0144ski","year":"2021","unstructured":"Pawli\u0144ski \u0141, Polus A, Ka\u0142u\u017cna M, Sordyl M, Tob\u00f3r-\u015awi\u0119tek E, Krawczyk M, et al. Gene expression with corresponding pathways analysis in Gaucher disease. Exp Mol Pathol. 2021;123:104679. https:\/\/doi.org\/10.1016\/j.yexmp.2021.104679.","journal-title":"Exp Mol Pathol"},{"key":"645_CR210","doi-asserted-by":"publisher","first-page":"5157645","DOI":"10.1155\/2018\/5157645","volume":"2018","author":"VJ Miller","year":"2018","unstructured":"Miller VJ, Villamena FA, Volek JS. Nutritional ketosis and mitohormesis: potential implications for mitochondrial function and human health. J Nutr Metab. 2018;2018:5157645. https:\/\/doi.org\/10.1155\/2018\/5157645.","journal-title":"J Nutr Metab"},{"key":"645_CR211","doi-asserted-by":"publisher","first-page":"106050","DOI":"10.1016\/j.biocel.2021.106050","volume":"138","author":"C Qu","year":"2021","unstructured":"Qu C, Keijer J, Adjobo-Hermans MJW, van de Wal M, Schirris T, van Karnebeek C, et al. The ketogenic diet as a therapeutic intervention strategy in mitochondrial disease. Int J Biochem Cell Biol. 2021;138:106050. https:\/\/doi.org\/10.1016\/j.biocel.2021.106050.","journal-title":"Int J Biochem Cell Biol"},{"key":"645_CR212","doi-asserted-by":"publisher","unstructured":"Xu S, Tao H, Cao W, Cao L, Lin Y, Zhao S-M, et al. Ketogenic diets inhibit mitochondrial biogenesis and induce cardiac fibrosis. Signal Transduct Target Ther. 2021;6(1):54. https:\/\/doi.org\/10.1038\/s41392-020-00411-4.","DOI":"10.1038\/s41392-020-00411-4"},{"issue":"8","key":"645_CR213","doi-asserted-by":"publisher","first-page":"e9639","DOI":"10.7759\/cureus.9639","volume":"12","author":"JT Batch","year":"2020","unstructured":"Batch JT, Lamsal SP, Adkins M, Sultan S, Ramirez MN. Advantages and disadvantages of the ketogenic diet: a review article. Cureus. 2020;12(8):e9639. https:\/\/doi.org\/10.7759\/cureus.9639.","journal-title":"Cureus"},{"key":"645_CR214","doi-asserted-by":"publisher","unstructured":"Kaya E, Smith DA, Smith C, Morris L, Bremova-Ertl T, Cortina-Borja M, et al. Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Communications. 2020;3(1):fcaa148. https:\/\/doi.org\/10.1093\/braincomms\/fcaa148.","DOI":"10.1093\/braincomms\/fcaa148"},{"key":"645_CR215","doi-asserted-by":"publisher","first-page":"101674","DOI":"10.1016\/j.redox.2020.101674","volume":"37","author":"D Nolfi-Donegan","year":"2020","unstructured":"Nolfi-Donegan D, Braganza A, Shiva S. Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol. 2020;37:101674. https:\/\/doi.org\/10.1016\/j.redox.2020.101674.","journal-title":"Redox Biol"},{"key":"645_CR216","doi-asserted-by":"publisher","unstructured":"Bremova T, Malinov\u00e1 V, Amraoui Y, Mengel E, Reinke J, Koln\u00edkov\u00e1 M, et al. Acetyl-dl-leucine in Niemann-Pick type C: a case series. Neurology. 2015;85(16):1368\u201375. https:\/\/doi.org\/10.1212\/WNL.0000000000002041.","DOI":"10.1212\/WNL.0000000000002041"},{"issue":"3","key":"645_CR217","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/nu2030355","volume":"2","author":"PCJN Calder","year":"2010","unstructured":"Calder PCJN. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;2(3):355\u201374. https:\/\/doi.org\/10.3390\/nu2030355.","journal-title":"Nutrients."},{"issue":"4","key":"645_CR218","doi-asserted-by":"publisher","first-page":"Cd002201","DOI":"10.1002\/14651858.CD002201.pub6","volume":"4","author":"H Watson","year":"2020","unstructured":"Watson H, Stackhouse C. Omega-3 fatty acid supplementation for cystic fibrosis. Cochrane Database Syst Rev. 2020;4(4):Cd002201. https:\/\/doi.org\/10.1002\/14651858.CD002201.pub6.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"645_CR219","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.clnu.2018.04.017","volume":"38","author":"E Oikonomou","year":"2019","unstructured":"Oikonomou E, Vogiatzi G, Karlis D, Siasos G, Chrysohoou C, Zografos T, et al. Effects of omega-3 polyunsaturated fatty acids on fibrosis, endothelial function and myocardial performance, in ischemic heart failure patients. Clin Nutr. 2019;38(3):1188\u201397. https:\/\/doi.org\/10.1016\/j.clnu.2018.04.017.","journal-title":"Clin Nutr"},{"issue":"5","key":"645_CR220","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1161\/circulationaha.115.019949","volume":"134","author":"B Heydari","year":"2016","unstructured":"Heydari B, Abdullah S, Pottala JV, Shah R, Abbasi S, Mandry D, et al. Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial. Circulation. 2016;134(5):378\u201391. https:\/\/doi.org\/10.1161\/circulationaha.115.019949.","journal-title":"Circulation"},{"key":"645_CR221","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fphys.2017.00039","volume":"8","author":"A Oliv\u00e1n-Viguera","year":"2017","unstructured":"Oliv\u00e1n-Viguera A, Lozano-Gerona J, L\u00f3pez de Frutos L, Cebolla JJ, Ir\u00fan P, Abarca-Lachen E, et al. Inhibition of intermediate-conductance calcium-activated K channel (KCa3.1) and fibroblast mitogenesis by \u03b1-linolenic acid and alterations of channel expression in the lysosomal storage disorders, Fabry disease, and Niemann Pick C. Front Physiol. 2017;8:39. https:\/\/doi.org\/10.3389\/fphys.2017.00039.","journal-title":"Front Physiol."},{"issue":"4","key":"645_CR222","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1159\/000430298","volume":"36","author":"CH Ju","year":"2015","unstructured":"Ju CH, Wang XP, Gao CY, Zhang SX, Ma XH, Liu C. Blockade of KCa3.1 attenuates left ventricular remodeling after experimental myocardial infarction. Cell Physiol Biochem. 2015;36(4):1305\u201315. https:\/\/doi.org\/10.1159\/000430298.","journal-title":"Cell Physiol Biochem."},{"issue":"1","key":"645_CR223","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1161\/atvbaha.113.302200","volume":"34","author":"S Choi","year":"2014","unstructured":"Choi S, Kim JA, Na HY, Cho SE, Park S, Jung SC, et al. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in Fabry disease. Arterioscler Thromb Vasc Biol. 2014;34(1):81\u20139. https:\/\/doi.org\/10.1161\/atvbaha.113.302200.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"1","key":"645_CR224","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/blood.V130.Suppl_1.3562.3562","volume":"130","author":"P Giraldo","year":"2017","unstructured":"Giraldo P, Cebolla JJ, Irun P, Lopez de Frutos L, Andrade-Campos M, K\u00f6hler RJB. Defective Function of KCa3. 1 Channels in Lysosomal Storage Disorders. Blood. 2017;130(Supplement 1):3562. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.3562.3562.","journal-title":"Mol Gen Metab."},{"issue":"8","key":"645_CR225","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1248\/bpb.b18-00078","volume":"41","author":"S Ohya","year":"2018","unstructured":"Ohya S, Kito H. Ca(2+)-activated K(+) channel K(Ca)3.1 as a therapeutic target for immune disorders. Biol Pharm Bull. 2018;41(8):1158\u201363. https:\/\/doi.org\/10.1248\/bpb.b18-00078.","journal-title":"Biol Pharm Bull."},{"issue":"1","key":"645_CR226","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3892\/ijmm.2018.3582","volume":"42","author":"W Huang","year":"2018","unstructured":"Huang W, Li ML, Xia MY, Shao JY. Fisetin-treatment alleviates airway inflammation through inhibition of MyD88\/NF-\u03baB signaling pathway. Int J Mol Med. 2018;42(1):208\u201318. https:\/\/doi.org\/10.3892\/ijmm.2018.3582.","journal-title":"Int J Mol Med"},{"issue":"2","key":"645_CR227","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2174\/1872213x13666190426164124","volume":"13","author":"G Mart\u00ednez","year":"2019","unstructured":"Mart\u00ednez G, Mijares MR, De Sanctis JB. Effects of flavonoids and its derivatives on immune cell responses. Recent Pat Inflamm Allergy Drug Dis. 2019;13(2):84\u2013104. https:\/\/doi.org\/10.2174\/1872213x13666190426164124.","journal-title":"Recent Pat Inflamm Allergy Drug Dis"},{"key":"645_CR228","doi-asserted-by":"publisher","first-page":"912031","DOI":"10.1155\/2013\/912031","volume":"2013","author":"GE Hong","year":"2013","unstructured":"Hong GE, Kim JA, Nagappan A, Yumnam S, Lee HJ, Kim EH, et al. Flavonoids identified from Korean Scutellaria baicalensis Georgi inhibit inflammatory signaling by suppressing activation of NF- \u03ba B and MAPK in RAW 264.7 cells. Evid-based Complement Altern Med: eCAM. 2013;2013:912031. https:\/\/doi.org\/10.1155\/2013\/912031.","journal-title":"Evid-based Complement Altern Med: eCAM."},{"issue":"4","key":"645_CR229","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3945\/jn.110.133843","volume":"141","author":"R Landberg","year":"2011","unstructured":"Landberg R, Sun Q, Rimm EB, Cassidy A, Scalbert A, Mantzoros CS, et al. Selected dietary flavonoids are associated with markers of inflammation and endothelial dysfunction in U.S. women. J Nutr. 2011;141(4):618\u201325. https:\/\/doi.org\/10.3945\/jn.110.133843.","journal-title":"J Nutr."},{"issue":"4","key":"645_CR230","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/jn\/138.4.753","volume":"138","author":"OK Chun","year":"2008","unstructured":"Chun OK, Chung SJ, Claycombe KJ, Song WO. Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in U.S. adults. J Nutr. 2008;138(4):753\u201360. https:\/\/doi.org\/10.1093\/jn\/138.4.753.","journal-title":"J Nutr."},{"issue":"6","key":"645_CR231","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1159\/000484304","volume":"43","author":"Y Liu","year":"2017","unstructured":"Liu Y, Gao L, Guo S, Liu Y, Zhao X, Li R, et al. Kaempferol alleviates angiotensin II-induced cardiac dysfunction and interstitial fibrosis in mice. Cell Physiol Biochem: Int J Exp Cell Physiol Biochem Pharmac. 2017;43(6):2253\u201363. https:\/\/doi.org\/10.1159\/000484304.","journal-title":"Cell Physiol Biochem: Int J Exp Cell Physiol Biochem Pharmac"},{"key":"645_CR232","doi-asserted-by":"publisher","first-page":"4957573","DOI":"10.1155\/2018\/4957573","volume":"2018","author":"Q Wang","year":"2018","unstructured":"Wang Q, Sui X, Sui DJ, Yang P. Flavonoid extract from propolis inhibits cardiac fibrosis triggered by myocardial infarction through upregulation of SIRT1. Evid-based Complement Altern Med: eCAM. 2018;2018:4957573. https:\/\/doi.org\/10.1155\/2018\/4957573.","journal-title":"Evid-based Complement Altern Med: eCAM"},{"key":"645_CR233","doi-asserted-by":"publisher","first-page":"5876841","DOI":"10.1155\/2021\/5876841","volume":"2021","author":"X Chang","year":"2021","unstructured":"Chang X, Zhang T, Wang J, Liu Y, Yan P, Meng Q, et al. SIRT5-related desuccinylation modification contributes to quercetin-induced protection against heart failure and high-glucose-prompted cardiomyocytes injured through regulation of mitochondrial quality surveillance. Oxid Med Cell Longev. 2021;2021:5876841. https:\/\/doi.org\/10.1155\/2021\/5876841.","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"645_CR234","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/fjc.0000000000000713","volume":"74","author":"Y Du","year":"2019","unstructured":"Du Y, Han J, Zhang H, Xu J, Jiang L, Ge W. Kaempferol prevents against Ang II-induced cardiac remodeling through attenuating Ang II-induced inflammation and oxidative stress. J Cardiovasc Pharmacol. 2019;74(4):326\u201335. https:\/\/doi.org\/10.1097\/fjc.0000000000000713.","journal-title":"J Cardiovasc Pharmacol"},{"key":"645_CR235","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ejmech.2018.06.053","volume":"155","author":"RV Patel","year":"2018","unstructured":"Patel RV, Mistry BM, Shinde SK, Syed R, Singh V, Shin HS. Therapeutic potential of quercetin as a cardiovascular agent. Eur J Med Chem. 2018;155:889\u2013904. https:\/\/doi.org\/10.1016\/j.ejmech.2018.06.053.","journal-title":"Eur J Med Chem"},{"key":"645_CR236","doi-asserted-by":"publisher","first-page":"739615","DOI":"10.3389\/fphar.2021.739615","volume":"12","author":"WJ Chen","year":"2021","unstructured":"Chen WJ, Cheng Y, Li W, Dong XK, Wei JL, Yang CH, et al. Quercetin attenuates cardiac hypertrophy by inhibiting mitochondrial dysfunction through SIRT3\/PARP-1 pathway. Front Pharmacol. 2021;12:739615. https:\/\/doi.org\/10.3389\/fphar.2021.739615.","journal-title":"Front Pharmacol"},{"issue":"12","key":"645_CR237","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.bbabio.2011.09.022","volume":"1807","author":"R Lagoa","year":"2011","unstructured":"Lagoa R, Graziani I, Lopez-Sanchez C, Garcia-Martinez V, Gutierrez-Merino C. Complex I and cytochrome C are molecular targets of flavonoids that inhibit hydrogen peroxide production by mitochondria. Biochem Biophys Acta. 2011;1807(12):1562\u201372. https:\/\/doi.org\/10.1016\/j.bbabio.2011.09.022.","journal-title":"Biochem Biophys Acta"},{"issue":"3","key":"645_CR238","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","volume":"95","author":"JS Shen","year":"2008","unstructured":"Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008;95(3):163\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2008.06.016.","journal-title":"Mol Genet Metab"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-024-00645-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T11:31:20Z","timestamp":1710156680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-024-00645-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":238,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s11897-024-00645-1","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"5 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vasco Sequeira is supported by a research grant from Bristol Myers Squibb (BMS).\u00a0Christoph Maack is an advisor to Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myer Squibb, Novo Nordisk, and Servier and received speaker honoraria from AstraZeneca, Bayer, Bristol Myer Squibb, Boehringer Ingelheim, Berlin Chemie, Edwards, Novartis, Novo Nordisk, and Servier. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}